<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US7148211 - Improved water solubility; drug delivery; avoids irritation - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Improved water solubility; drug delivery; avoids irritation"><meta name="DC.contributor" content="Richard B. Mazess" scheme="inventor"><meta name="DC.contributor" content="Jeffrey W. Driscoll" scheme="inventor"><meta name="DC.contributor" content="Creighton Reed Goldensoph" scheme="inventor"><meta name="DC.contributor" content="Leon W. LeVan" scheme="inventor"><meta name="DC.contributor" content="Genzyme Corporation" scheme="assignee"><meta name="DC.date" content="2002-9-18" scheme="dateSubmitted"><meta name="DC.description" content="The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same."><meta name="DC.date" content="2006-12-12" scheme="issued"><meta name="DC.relation" content="US:2383446" scheme="references"><meta name="DC.relation" content="US:3697559" scheme="references"><meta name="DC.relation" content="US:3741996" scheme="references"><meta name="DC.relation" content="US:3907843" scheme="references"><meta name="DC.relation" content="US:3932634" scheme="references"><meta name="DC.relation" content="US:4075333" scheme="references"><meta name="DC.relation" content="US:4160803" scheme="references"><meta name="DC.relation" content="US:4195027" scheme="references"><meta name="DC.relation" content="US:4202829" scheme="references"><meta name="DC.relation" content="US:4225596" scheme="references"><meta name="DC.relation" content="US:4234495" scheme="references"><meta name="DC.relation" content="US:4260549" scheme="references"><meta name="DC.relation" content="US:4308264" scheme="references"><meta name="DC.relation" content="US:4362710" scheme="references"><meta name="DC.relation" content="US:4364941" scheme="references"><meta name="DC.relation" content="US:4391802" scheme="references"><meta name="DC.relation" content="US:4508651" scheme="references"><meta name="DC.relation" content="US:4554106" scheme="references"><meta name="DC.relation" content="US:4555364" scheme="references"><meta name="DC.relation" content="US:4588716" scheme="references"><meta name="DC.relation" content="US:4661294" scheme="references"><meta name="DC.relation" content="US:4689180" scheme="references"><meta name="DC.relation" content="US:4698328" scheme="references"><meta name="DC.relation" content="US:4717721" scheme="references"><meta name="DC.relation" content="US:4727064" scheme="references"><meta name="DC.relation" content="US:4784845" scheme="references"><meta name="DC.relation" content="US:4816247" scheme="references"><meta name="DC.relation" content="US:4833125" scheme="references"><meta name="DC.relation" content="US:4866048" scheme="references"><meta name="DC.relation" content="US:4877778" scheme="references"><meta name="DC.relation" content="US:4902481" scheme="references"><meta name="DC.relation" content="US:4948788" scheme="references"><meta name="DC.relation" content="US:4948789" scheme="references"><meta name="DC.relation" content="US:5063221" scheme="references"><meta name="DC.relation" content="US:5085864" scheme="references"><meta name="DC.relation" content="US:5092840" scheme="references"><meta name="DC.relation" content="US:5104864" scheme="references"><meta name="DC.relation" content="US:5120720" scheme="references"><meta name="DC.relation" content="US:5124152" scheme="references"><meta name="DC.relation" content="US:5134127" scheme="references"><meta name="DC.relation" content="US:5141719" scheme="references"><meta name="DC.relation" content="US:5157135" scheme="references"><meta name="DC.relation" content="US:5158944" scheme="references"><meta name="DC.relation" content="US:5182274" scheme="references"><meta name="DC.relation" content="US:5205989" scheme="references"><meta name="DC.relation" content="US:5219528" scheme="references"><meta name="DC.relation" content="US:5232836" scheme="references"><meta name="DC.relation" content="US:5260290" scheme="references"><meta name="DC.relation" content="US:5264184" scheme="references"><meta name="DC.relation" content="US:5264618" scheme="references"><meta name="DC.relation" content="US:5298246" scheme="references"><meta name="DC.relation" content="US:5334740" scheme="references"><meta name="DC.relation" content="US:5338532" scheme="references"><meta name="DC.relation" content="US:5360413" scheme="references"><meta name="DC.relation" content="US:5366965" scheme="references"><meta name="DC.relation" content="US:5372996" scheme="references"><meta name="DC.relation" content="US:5376645" scheme="references"><meta name="DC.relation" content="US:5403831" scheme="references"><meta name="DC.relation" content="US:5417923" scheme="references"><meta name="DC.relation" content="US:5474923" scheme="references"><meta name="DC.relation" content="US:5487900" scheme="references"><meta name="DC.relation" content="US:5488120" scheme="references"><meta name="DC.relation" content="US:5527524" scheme="references"><meta name="DC.relation" content="US:5532229" scheme="references"><meta name="DC.relation" content="US:5549577" scheme="references"><meta name="DC.relation" content="US:5554386" scheme="references"><meta name="DC.relation" content="US:5561123" scheme="references"><meta name="DC.relation" content="US:5565442" scheme="references"><meta name="DC.relation" content="US:5597575" scheme="references"><meta name="DC.relation" content="US:5602116" scheme="references"><meta name="DC.relation" content="US:5614513" scheme="references"><meta name="DC.relation" content="US:5632315" scheme="references"><meta name="DC.relation" content="US:5637742" scheme="references"><meta name="DC.relation" content="US:5645856" scheme="references"><meta name="DC.relation" content="US:5661025" scheme="references"><meta name="DC.relation" content="US:5668174" scheme="references"><meta name="DC.relation" content="US:5691328" scheme="references"><meta name="DC.relation" content="US:5716346" scheme="references"><meta name="DC.relation" content="US:5739271" scheme="references"><meta name="DC.relation" content="US:5763428" scheme="references"><meta name="DC.relation" content="US:5763429" scheme="references"><meta name="DC.relation" content="US:5766582" scheme="references"><meta name="DC.relation" content="US:5795882" scheme="references"><meta name="DC.relation" content="US:5798345" scheme="references"><meta name="DC.relation" content="US:5804573" scheme="references"><meta name="DC.relation" content="US:5817648" scheme="references"><meta name="DC.relation" content="US:5827883" scheme="references"><meta name="DC.relation" content="US:5858999" scheme="references"><meta name="DC.relation" content="US:5869386" scheme="references"><meta name="DC.relation" content="US:5874418" scheme="references"><meta name="DC.relation" content="US:5880114" scheme="references"><meta name="DC.relation" content="US:5932544" scheme="references"><meta name="DC.relation" content="US:5939407" scheme="references"><meta name="DC.relation" content="US:5965160" scheme="references"><meta name="DC.relation" content="US:5972917" scheme="references"><meta name="DC.relation" content="US:6045538" scheme="references"><meta name="DC.relation" content="US:6046177" scheme="references"><meta name="DC.relation" content="US:6051567" scheme="references"><meta name="DC.relation" content="US:6096338" scheme="references"><meta name="DC.relation" content="US:6136799" scheme="references"><meta name="DC.relation" content="US:6171603" scheme="references"><meta name="DC.relation" content="US:6211169" scheme="references"><meta name="citation_reference" content="Abood et al., &quot;Pharmacy Practice and the Law,&quot; (1994) pp. 27-28."><meta name="citation_reference" content="Aloia, J. et al., Amer. J. Med., (1988) 84:401-08."><meta name="citation_reference" content="Barton, D. et al., &quot;Synthetic Uses of Steroidal Ring &amp; Diene Protection: 22,23-Dihydroergosterol,&quot; JCS Perkin I, (1976) pp. 821-826."><meta name="citation_reference" content="Beer, et al., &quot;A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies,&quot; Cancer, (Jun. 15, 2001) 91:12:2431-2439."><meta name="citation_reference" content="Beer, et al., &quot;Weekly High-Dose Calcitriol and Docetaxel in Advanced Prostate Cancer,&quot; Seminars in Oncology, Suppl 15 (Aug. 2001) 28:4:49-55."><meta name="citation_reference" content="Beer, T. et al., &quot;Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer,&quot; Journal of Clinical Oncology, (Jan. 2003) 21:1:123-128."><meta name="citation_reference" content="Blazsek, I. et al. &quot;Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1alpha,25 Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;, and Prednisone,&quot; 16:4:259-264 (Abstract)."><meta name="citation_reference" content="Braunwald, E. et al., Harrison&#39;s Principles of Internal Medicine: Part Eleven, &quot;Disorders of Bone and Mineral Metabolism,&quot; Chapter 335, McGraw-Hill, New York, (1987) pp. 1860-1865."><meta name="citation_reference" content="Brautbar, N. &quot;Osteoporosis: Is 1,25-(OH)2D3 of Value in Treatment?&quot; Nephron (1986) 44:161-166."><meta name="citation_reference" content="Brown, J.P. et al., &quot;Serum Bone Gala-Protein: A Specific Marker for Bone Formation in Postmenopausal Osteoporosis,&quot; Lancet, (1984) 1:1091-1093."><meta name="citation_reference" content="Caniggia, A. et al., &quot;Effect of a Long-Term Treatment with 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;on Osteocalcin in Postmenopausal Osteoporosis,&quot; Cacified Tissue Int., (1986) 38:328-332."><meta name="citation_reference" content="Cho, Y.L. et al., &quot;Combined Effects of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Platinum Drugs on the growth of MCF-7 Cells,&quot; Cancer Research, (Jun. 1991) 51:2848-2853."><meta name="citation_reference" content="Christiansen, C. et al., &quot;Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females,&quot; Europ J Clin Inves., (1980) 10:273-279."><meta name="citation_reference" content="Christiansen, C. et al., Eur. J. Clin. Invest., (1981) 11:305-309."><meta name="citation_reference" content="Crump, D.R. et al., &quot;(22S)-Hydroxyvitamin D&lt;SUB&gt;4&lt;/SUB&gt;,&quot; J.C.S. Perkins Trans. I, (1973) pp. 2731-2733."><meta name="citation_reference" content="Defacque, H. et al., &quot;Different Combinations of Retinoids and Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines,&quot; J. Pharmacology and Experimental Therapeutics, (1994) 271:193-199."><meta name="citation_reference" content="DeLuca et al., &quot;Synthesis, Biological Activity, and Metabolism of 22,23-&lt;SUP&gt;3&lt;/SUP&gt;H-Vitamin D&lt;SUB&gt;4&lt;/SUB&gt;,&quot; Arch. Biochem, Biophys., (1968) 124:122-128."><meta name="citation_reference" content="Duda et al., &quot;1,25-Dihydroxyvitamin D Stimulation Test for Osteoblast Function in Normal and Osteoporotic Postmenopausal Women,&quot; J. Clinic Inves., (1987) 79:1249-1253."><meta name="citation_reference" content="Endo, K. et al., &quot;Effect of Combination Treatment with Vitamin D Analog (OCT) and a Biophosphonate (AHPrBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia,&quot; Journal of Bone and Mineral Research, (1998) 13:9:1378-1383."><meta name="citation_reference" content="Foldes, J. et al., &quot;Long Term Treatment with 1alpha (OH)D&lt;SUB&gt;3 &lt;/SUB&gt;for Postmenopausal Osteoporosis: Efficacy and Safety,&quot; Osteoporosis, (1987) 2:971-973."><meta name="citation_reference" content="Gallagher, J.C. et al., &quot;Effects of Increasing Doses of 1alpha-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;on Calcium Homeostasis in Postmenopausal Osteopenic Women,&quot; J. Bone Min. Res., (1994) 9:607-614."><meta name="citation_reference" content="Gallagher, J.C., et al., Annals of Int. Med., (1990) 13:649-655."><meta name="citation_reference" content="Grab, W. Z. Physiol. Chem., (1936) 243:63-89."><meta name="citation_reference" content="Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, (1979) pp. 5-6."><meta name="citation_reference" content="Hershberger, P. et al. &quot;Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis,&quot; Clinical Cancer Research, (Apr. 2001) 7:1043-1051."><meta name="citation_reference" content="Hoikka, V. et al., &quot;Treatment of Osteoporosis with 1-Alpha-Hydroxycholecalciferol and Calcium,&quot; Acta. Med. Scand.(1980) 207:221-224."><meta name="citation_reference" content="Holick, M.F. et al., Proc. Natl. Acad. Sci. USA, (1971) 68:803-804."><meta name="citation_reference" content="Holick, M.F. et al., Science (1973) pp. 180, 190-191."><meta name="citation_reference" content="Holick, M.F., &quot;Noncalcemic Actions of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Clinical Applications&quot;, Bone, (1995) 17:2:107S-110S."><meta name="citation_reference" content="Horst et al., &quot;Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick,&quot; Biochem. J., (1982) 204:185-189."><meta name="citation_reference" content="Horst et al., &quot;Quantitation of Vitamin D and its Metabolites and Their Plasma Concentrations in Five Species of Animals,&quot; Anal. Biochem., (1981) 116:189-203."><meta name="citation_reference" content="Jensen, G.F. et al., Clin. Endocrinol., (1982) 16:515-524."><meta name="citation_reference" content="Johnson, C. et al. &quot;Vitamin D-related Therapies in Prostate Cancer,&quot; Cancer and Metastasis Review 21, (2002) pp. 147-158."><meta name="citation_reference" content="Kanis, J.A. et al., &quot;Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis,&quot; Osteoporosis Int., (1991) 1:182-188."><meta name="citation_reference" content="Kim, S. et al., Potentiation of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;-Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone, Biochem. Pharmacology, (2002) 64:1233-1242."><meta name="citation_reference" content="Knutson, et al., &quot;Metabolism of 1 alpha-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;to activated Dihydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;Metabolites Decreases Endogenous 1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;in Rats and Monkeys,&quot; Endocrinology, (1995) 136:11:4749-4753."><meta name="citation_reference" content="Kocienski, P.J. et al., &quot;Calciferol and its Relatives. A Synthesis of Vitamin D&lt;SUB&gt;4&lt;/SUB&gt;,&quot; J.C.S. Perkins I, (1979) pp. 1290-1293."><meta name="citation_reference" content="Lam, H.Y. et al., Science , (1974) 486:1038-1040."><meta name="citation_reference" content="Londowski, J.M. et al., &quot;Biological Activity of the C-1, C-3, C-25, beta-D-Glucopyranosides of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;&lt;SUP&gt;1&lt;/SUP&gt;,&quot; J. Pharmacology Expr. Ther., (1986) 237:3:837-840."><meta name="citation_reference" content="Majewski, et al., &quot;Inhibition of Tumor Cell-Induced Angiogenisis by Retinoids, 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and their Combination,&quot; Cancer Letters, (1993) 75:35-39."><meta name="citation_reference" content="Martin and DeLuca, &quot;Calcium Transport,&quot; Am. J. Physiol., 216:1352-1359."><meta name="citation_reference" content="Mathias, C.J. et al., &quot;Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate,&quot; J. Nucl. Med. (1996), 37(6):1003-1008."><meta name="citation_reference" content="McDonald, F.G., &quot;The Multiple Nature of Vitamin D,&quot; J. Biol. Chem. 114, (1936) 1xv."><meta name="citation_reference" content="Merck Index, S. Budavari (ed.), 11th ed., Merck &amp; Co., Rahway, N.J. (1989) pp. 1579, #9930."><meta name="citation_reference" content="Miller et al., &quot;The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;&lt;SUP&gt;1&lt;/SUP&gt;,&quot; Cancer Res., (1992) 52:515-520."><meta name="citation_reference" content="Moffatt, K. et al., &quot;1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines,&quot; Clinical Cancer Research, (Mar. 1999) 5:695-703."><meta name="citation_reference" content="Muindi, J. et al., &quot;Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase 1 Trial of Calcitriol and Paclitaxel,&quot; Clinical Pharmacology &amp; Therapeutics, (Dec. 2002) pp. 648-659."><meta name="citation_reference" content="Nemeto, H. et al., &quot;A Stereoselective Synthesis of 1 alpha-Hydroxy-Vitamin D&lt;SUB&gt;3&lt;/SUB&gt;,&quot; Chemistry Letters, (1985) 8:1131-1132."><meta name="citation_reference" content="Orimo, H. et al., &quot;Reduced Occurrence of Vertebral Crush Fractures in Senile Osteoporosis Treated with 1alpha(OH)-Vitamin D&lt;SUB&gt;3&lt;/SUB&gt;,&quot; Bone and Mineral, (1987) 3:47-52."><meta name="citation_reference" content="Ott, S.M. and C.H. Chestnut, Annals of Int. Med., (1989) 110:267-274."><meta name="citation_reference" content="Paaren et al., &quot;Direct C(1) Hydroxylation of Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Related Compounds,&quot; J. Org. Chem., (1980) 45:3253."><meta name="citation_reference" content="Packman, K. et al. &quot;Combination Treatment of MCF-7 Xenografts with the Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Analog EB1089 and Antiestrogens,&quot; (Vitamin D Endocrine Workshop, Nashville, TN May 27-Jun. 1, 2000) pp. 511-514."><meta name="citation_reference" content="Parfitt, &quot;Martindale, The Complete Drug Reference,&quot; (1999) pp. 1366-1369."><meta name="citation_reference" content="Physicians&#39;s Desk Reference, Edition 43:1746-1748."><meta name="citation_reference" content="Podenphant, J. et al., &quot;Serum Bone Gla Protein and Other Biochemical Estimates of Bone Turnover in Early Postmenopausal Women During Prophylactic Treatment for Osteoporosis,&quot; Acta Med Scand, (1985) 218:329-333."><meta name="citation_reference" content="Pouilles, J.M. et al., &quot;Prevention of Early Postmenopausal Bone Loss with 1alpha-Hydroxy Vitamin D&lt;SUB&gt;3&lt;/SUB&gt;, A Three-Year Prospective Study,&quot; Clin Rheumatol. 11, 4 (1992) pp. 492-497."><meta name="citation_reference" content="Ravid, A. et al., &quot;1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Enhances the Susceptibility of Brease Cancer Cells to Doxorubicin-induced Oxidative Damage,&quot; Cancer Research, (Feb. 15, 1999) 59:862-867."><meta name="citation_reference" content="Reeve, L.E. et al., &quot;Biological Activity of 1alpha-hydroxy Vitamin D&lt;SUB&gt;2 &lt;/SUB&gt;in the Rat,&quot; Arch. Biochem. Biophys. (Feb. 1978) 186:1:164-167."><meta name="citation_reference" content="Sato, F. et al., &quot;Biological Activity of 1alpha,25-Dihydroxyvitamin D Derivatives-24-epi-1alpha,25-Dihydroxyvitamin D-2 and 1alpha,25-Dihydroxyvitamin D-7,&quot; Biochim. Biophys. Acta, (1991) 1091:188-192."><meta name="citation_reference" content="Shiraki, M. et al., Endocrinol. Japan, (1985) 32:305-315."><meta name="citation_reference" content="Siwinska, A. et al. &quot;Potentiation of the Antiproliferative Effect in Vitro of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D,&quot; Anticancer Research, (2001) 21:1925-1929."><meta name="citation_reference" content="Sjoden et al., &quot;Effects of 1 OHD&lt;SUB&gt;2 &lt;/SUB&gt;on Bone Tissue,&quot; Acta. Endocrinol. (Copenh.) (Aug. 1984) 16:4:564-568."><meta name="citation_reference" content="Sjoden, G. et al., &quot;1alpha-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;is Less Toxic than 1alpha-Hydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;in the Rat,&quot; Proc. Soc. Exp. Biol. Med., (1985) 178:432-436."><meta name="citation_reference" content="Sjoden, G. et al., &quot;Antirachitic Activity of 1alpha-Hydroxyergocalciferol and 1alpha-Hydroxycholecalciferol in Rats,&quot; J. Nutr., (1984) 114:2043-2046."><meta name="citation_reference" content="Skowronski et al., &quot;Actions Of Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;,&quot; Endocrinology, (1995) 136:20-26."><meta name="citation_reference" content="Skowronski et al., &quot;Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Receptors and Actions in Human Prostate Cancer Cell Lines,&quot; Endocrinology, (1993) 132:1952-1960."><meta name="citation_reference" content="Slapak, C. et al., &quot;Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol,&quot; Amer. J. Hematology, (1992) 41:178-183."><meta name="citation_reference" content="Sommerfeldt et al., &quot;Metabolism of Orally Administered [&lt;SUP&gt;3&lt;/SUP&gt;H]Ergocalciferol and [&lt;SUP&gt;3&lt;/SUP&gt;H]Cholecalciferol by Dairy Calves,&quot; J. Nutr., (1983) 11:2595-2600."><meta name="citation_reference" content="Song, X.D. et al., &quot;Bryostatin-1 and 1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Synergistically Stimulated the Differentiation of NB4 Acute Promyelocytic Leukemia Cells,&quot; Leukemia, (1999) 13:275-281."><meta name="citation_reference" content="Sorensen, O.H. et al., Clin. Endocrinol., (1977) 7:169S-175S."><meta name="citation_reference" content="Strugnell et al., &quot;1 alpha,24(S)-Dihydroxyvitamin D&lt;SUB&gt;2&lt;/SUB&gt;: a biologically active product of 1 alpha-hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;made in the human hepatoma, Hep3B,&quot; Biochem. J., (1995) 310-233-241."><meta name="citation_reference" content="Strugnell et al., &quot;Metabolism of a Cyclopropane-Ring-Containing Analog of 1alpha-Hydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;in a Hepatocyte Cell Model,&quot; Biochem. Pharm., (1990) 40:333-341."><meta name="citation_reference" content="Studzinski, G. et al., &quot;Potentiation by 1-alpha,25- Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea,&quot; J. National Cancer Inst., (Apr. 1986) 76:4:641-648."><meta name="citation_reference" content="Suzuki, Y. et al., &quot;The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell-The Combination with the Growth Factor Interaction Inhibitor (Suramin),&quot; Acta Urologica (1993) 12:1215-1220, (Abstract)."><meta name="citation_reference" content="Swami, S. et al. &quot;1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells,&quot; Clinical Cancer Research, (Aug. 2000) 6:3371-3379."><meta name="citation_reference" content="Tachibana, Y. (Nisshin Flour Milling Co.), &quot;Preparation of 1Beta-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;and D&lt;SUB&gt;3&lt;/SUB&gt;,&quot; Chemical Abstracts, (1990) 113:1:6688 Col. 2 Abstract No. 6683y."><meta name="citation_reference" content="Tanaka, Y. et al., Endocrinology (1973) 92:417-422."><meta name="citation_reference" content="Torres, R. et al., Etoposide Stimulates 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells, Molecular and Cellular Biochemistry, (2000) 208:157-162."><meta name="citation_reference" content="Tsuji, M. et al., &quot;Synthesis of 22,23-Dihydro-1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;and its 24R-Epimer, New Vitamin D&lt;SUB&gt;2 &lt;/SUB&gt;Derivatives,&quot; Bull. Chem. Soc. Jpn., (1990) 63:8:2233-2238."><meta name="citation_reference" content="Wang, Q. et al., &quot;1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death,&quot; Cancer Research, (Apr. 2000) 60:2040-2048."><meta name="citation_reference" content="Wang, X. et al., &quot;Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;-Induced Differentiation of Human Leukemia HL60 Cells,&quot; Experimental Cell Research, (2000) 258:425-437."><meta name="citation_reference" content="Wientroub, S. et al. &quot;The Dichotomy in the Effects of 1,25 Dihydroxy Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and 24, 25 Dihydroxy Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in Vitamin D-Deficient Rats,&quot; Calcif, Tissue Int., (1987) 40:166-172."><meta name="citation_reference" content="Windaus, A. et al., &quot;Uber das Krystallisierte Vitamin D&lt;SUB&gt;4&lt;/SUB&gt;,&quot; Z. Physiol. Chem., (1937) 247:185-188."><meta name="citation_reference" content="Yu, W. et al., &quot;Enhancement of 1,25- Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;- Mediated Antitumor Activity with Dexamethasone,&quot; J. National Cancer Inst., (Jan. 1998) 90:2:134-141."><meta name="citation_reference" content="Zerwekh et al., &quot;Short-Term 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Administration Raises Serum Osteocalcin in Patients with Postmenopausal Osteoporosis,&quot; J. Clin. Endocrinol. Metabol, (1985) 60:615-617."><meta name="citation_patent_number" content="US:7148211"><meta name="citation_patent_application_number" content="US:10/247,765"><link rel="canonical" href="http://www.google.com/patents/US7148211"/><meta property="og:url" content="http://www.google.com/patents/US7148211"/><meta name="title" content="Patent US7148211 - Improved water solubility; drug delivery; avoids irritation"/><meta name="description" content="The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same."/><meta property="og:title" content="Patent US7148211 - Improved water solubility; drug delivery; avoids irritation"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("41DsU6O7JoqdogSH44C4Cg"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("CRI"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("41DsU6O7JoqdogSH44C4Cg"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("CRI"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us7148211?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US7148211"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=Mqx4BAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS7148211&amp;usg=AFQjCNFNhncUg8NydAcXpO3fi8cxaxnzgA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US7148211.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US7148211.pdf"></a><a class="appbar-application-grant-link" data-label="Application" href="/patents/US20040053894"></a><a class="appbar-application-grant-link" data-selected="true" data-label="Grant" href="/patents/US7148211"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US7148211" style="display:none"><span itemprop="description">The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same....</span><span itemprop="url">http://www.google.com/patents/US7148211?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US7148211 - Improved water solubility; drug delivery; avoids irritation</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US7148211 - Improved water solubility; drug delivery; avoids irritation" title="Patent US7148211 - Improved water solubility; drug delivery; avoids irritation"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US7148211 B2</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 10/247,765</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Dec 12, 2006</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Sep 18, 2002</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Sep 18, 2002</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2498331A1">CA2498331A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1684691A">CN1684691A</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN100349573C">CN100349573C</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1553956A2">EP1553956A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1553956A4">EP1553956A4</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20040053894">US20040053894</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20060183722">US20060183722</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20100197641">US20100197641</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20120214773">US20120214773</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2004026231A2">WO2004026231A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO2004026231A3">WO2004026231A3</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">10247765, </span><span class="patent-bibdata-value">247765, </span><span class="patent-bibdata-value">US 7148211 B2, </span><span class="patent-bibdata-value">US 7148211B2, </span><span class="patent-bibdata-value">US-B2-7148211, </span><span class="patent-bibdata-value">US7148211 B2, </span><span class="patent-bibdata-value">US7148211B2</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Richard+B.+Mazess%22">Richard B. Mazess</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Jeffrey+W.+Driscoll%22">Jeffrey W. Driscoll</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Creighton+Reed+Goldensoph%22">Creighton Reed Goldensoph</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Leon+W.+LeVan%22">Leon W. LeVan</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Genzyme+Corporation%22">Genzyme Corporation</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US7148211.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7148211.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US7148211.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (102),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (85),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (5),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (16),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (6)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/7148211&usg=AFQjCNHyrhymCpym_4uHpi5Ygjlkw6PBEA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D7148211&usg=AFQjCNEF50OdI8wgpyCpaoD1Ap_-tjylaQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D7148211B2%26KC%3DB2%26FT%3DD&usg=AFQjCNE5ftMFeR9CFudnaqRykmM_UkGszA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT129873249" lang="EN" load-source="ifi">Improved water solubility; drug delivery; avoids irritation</invention-title></span><br><span class="patent-number">US 7148211 B2</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA51082486" lang="EN" load-source="patent-office"> <div num="p-0001" class="abstract">The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(14)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US7148211-13.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US7148211-13.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(6)</span></span></div><div class="patent-text"><div mxw-id="PCLM9131877" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-00001" num="00001" class="claim">
      <div class="claim-text">1. A parenteral formulation, comprising a lipophilic drug which is doxercalciferol, a non-ionic solubilizer which is polysorbate 20 present at a concentration of about 0.05% to about 5% w/w, a lipophilic antioxidant which is butylated hydroxytoluene (BHT) present at a concentration of about 20 to about 2000 ppm, an optional agent which is ethanol present at a concentration of 0 to 30% w/w, and an aqueous vehicle.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00002" num="00002" class="claim">
      <div class="claim-text">2. A formulation as set forth in <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the optional agent is present in a concentration of 0% to about 10% w/w.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00003" num="00003" class="claim">
      <div class="claim-text">3. A formulalion as set forth in <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the optional agent is present in a concentration of about 1% to about 3% w/w.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00004" num="00004" class="claim">
      <div class="claim-text">4. A formulation as set forth in <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the non-ionic solubilizer includes 0.5%–2.5% w/w polysorbate 20, the lipophilic antioxidant includes 20 ppm BHT and the optional agent includes 2.5% w/w ethanol.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00005" num="00005" class="claim">
      <div class="claim-text">5. A formulation as set forth in <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein the doxercalciferol is present at a concentration of 2–10 μg/mL.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00006" num="00006" class="claim">
      <div class="claim-text">6. A parenteral formulation suitable for treatment of secondary hyperparathyroidism comprising 2–10 μg/mL of doxercalciferol 0.5%–2.5% w/w polysorbate 20, 20 ppm BHT and 2.5% w/w ethanol.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES16154421" lang="EN" load-source="patent-office" class="description">
    <heading>CROSS-REFERENCE TO RELATED APPLICATIONS</heading> <p num="p-0002">Not applicable.</p>
    <heading>STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT</heading> <p num="p-0003">Not Applicable</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p num="p-0004">This invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and uses for such formulations. The formulations are stable in aqueous-based vehicles, and have therapeutically and commercially useful concentrations of active ingredient.</p>
    <p num="p-0005">Many pharmacologically active substances are lipophilic, i.e., only sparingly or negligibly water-soluble. Lipophilic therapeutic agents span the entire range of biologically and/or pharmacologically active substances. For example, they include certain analgesics and anti-inflammatory agents, anti-asthma agents, anti-bacterial agents, anti-viral agents, anti-coagulants, anti-depressants, anti-neoplastic agents and immunosuppressants, β-blockers, corticosteroids, opioid analgesics, lipid regulating agents, anxiolytics, sedatives, hypnotics and neuroleptics.</p>
    <p num="p-0006">The poor water-solubility of these lipophilic agents often results in major difficulties in formulation, particularly when easily sterilizable and administrable homogeneous aqueous solutions are needed. Efficacious aqueous-based formulations are particularly problematic for systemic administration, in particular parenteral administration (i.e., injectable solutions) and for certain liquid preparations for, e.g., topical gynecologic, dermatologic ophthalmic, etc. use, and for use on the oral mucous membranes.</p>
    <p num="p-0007">A number of approaches for obtaining aqueous compositions of sparingly water-soluble drugs are known. Such approaches seek to increase the solubility, and accordingly, increase the ease of formulation and the bioavailability of the sparingly soluble or lipophilic active agents. One such approach involves chemical modification of the lipophilic drug by introduction of a ionic or ionizable group or a group that lowers the melting point. The former generally depends upon the lipophilic drug having a hydroxyl or carboxy group which can be used to form various kinds of esters. The latter is based on the concept that, to be solubilized, the molecules have to leave the crystal lattice. Any modification of the molecule that lowers the melting point, and thus reduces the energy of the crystal lattice, tends to increase the solubility thereof in any solvent.</p>
    <p num="p-0008">Another method involves physico-chemical solubilization techniques such as micellar solubilization by means of surface-active agents, i.e., the use of surfactant micelles to solubilize and transport the therapeutic agent. Micelles are agglomerates of colloidal dimensions formed by amphiphilic compounds under certain conditions. Micelles, and pharmaceutical compositions containing micelles, have been extensively studied and are described in detail in the literature. In aqueous solution, micelles can incorporate lipophilic therapeutic agents in the hydrocarbon core of the micelle, or can entangle the agents at various positions within the micelle walls. Although micellar formulations can solubilize a variety of lipophilic therapeutic agents, the loading capacity of conventional micelle formulations is limited by the solubility of the therapeutic agent in the micelle surfactant. For many lipophilic therapeutic agents, such solubility is too low to offer formulations that can deliver therapeutically effective doses.</p>
    <p num="p-0009">The formation of complexes, solid solutions and solid dispersions by means of the use of suitable polymers is another approach for increasing the water-solubility of pharmaceutically active substances. In such a case, the active ingredient is incorporated in a suitable hydrophilic carrier, which increases the solubility and the bioavailability thereof without any formal covalent bonds originating between the drug and the polymer matrix. The difference between a solid solution and a solid dispersion is typically in the form of the active ingredient. In a solid solution, the active is present in the amorphous molecular form, while in a dispersion the active is present in a crystalline form, as fine as possible.</p>
    <p num="p-0010">Even more widespread and studied is the use of the interaction between a polymer and a drug to give rise to a true complex, wherein chemical bonds of a noncovalent nature are involved. Complexing polymers employed in the pharmaceutical field include, e.g., polyethylene glycols, polypropylene glycols, cyclodextrins, carboxymethylcellulose, polyvinylpyrrolidone (PVP)</p>
    <p num="p-0011">Co-precipitation is yet another widespread method for the preparation of complexes with increased solubility. In this method, the substance and the polymer are dissolved in an organic solvent in which they are both soluble, and the solution is then evaporated at atmospheric pressure, under vacuum, by spray-drying or by lyophilization, to yield a dry product actually made of the complex of the treated drug. Such complexes can also be obtained by applying other methods, such as grinding and mixing the ingredients in a mill, or by extrusion of a paste containing the two products together with a minor amount of water, etc. In comparison with the starting drug, the complex typically shows an appreciably enhanced water-solubility.</p>
    <p num="p-0012">In devising a working method for solubilizing drugs by complexation, it is necessary to take into account the molecular weight of the polymer, since the solubility of the active ingredient directly depends thereon. In general, low molecular weights are more suitable than medium to high molecular weights.</p>
    <p num="p-0013">Still another method involves use of various co-solvent systems, i.e., compositions using a solvent mixture containing water and one or more organic solvents. One approach to solubilizing lipophilic drug agents in aqueous systems is to employ some combination of alcohols and glycols (PDA <i>J. Pharm. Sci. Technol. </i>50(5) 1996; U.S. Pat. Nos. 6,136,799; 6,361,758 and 5,858,999) Organic contents as high as 50% or more are often required to ensure solubility during manufacturing, storage and administration. Although organic levels while high will still be below the LD<sub>50 </sub>for a low volume parenteral dosage, the amounts are still typically undesirable. High levels of organic solvent can cause pain on injection and tissue necrosis.</p>
    <p num="p-0014">Other methods involve the formation of complexes by the addition of chelating agents such as citric acid, tartaric acid, amino acids, thioglycolic acid and edetate disodium. Others use buffering agents such as acetate, citrate, glutamate and phosphate salts. However, buffers and chelating agents have been implicated in imparting aluminum levels in products to in excess of 3.5 parts per million leading to adverse side effects. (International Patent Application Publication WO 96/36340) Moreover, certain chelating agents such as EDTA have be implicated in adverse effects such nephrotoxicity and renal tubular necrosis. (U.S. Pat. No. 6,361,758)</p>
    <p num="p-0015">Each of these foregoing methods has its inherent limitations. For many of the pharmaceutical substances, the solubility levels that can be achieved with one or another of the methods discussed above are still insufficient to make their use in aqueous-based commercial products viable.</p>
    <p num="p-0016">An exemplary and important class of lipophilic drug agents are the vitamin D compounds. Properly metabolized vitamin D compounds are necessary for the maintenance of healthy bones and have been found to display more other biological activities. The lipophilicity of the natural forms of vitamin D and of the many known synthetic analogs of vitamin D makes it difficult to manufacture an efficacious formulation, particularly, a parenteral formulation which is preferred for, e.g., renal dialysis patients.</p>
    <p num="p-0017">Additionally, vitamin D compounds, among other lipophilic compounds, are known to be oxygen sensitive, being oxidized when exposed to air, and thus, losing integrity. One approach to circumventing this problem is to add an antioxidant directly to a formulation of the drug. However, certain antioxidants, such as ascorbic acid and sodium ascorbate, which are highly water soluble, will discolor in the course of performing their intended function. Buffers and/or chelating agents have also been added to decrease oxygen sensitivity thus maintaining active drug potency (U.S. Pat. Nos. 4,308,264; 4,948,788 and 5,182,274.) However, as noted above, buffers and chelating agents are known to introduce undesirable levels of aluminum into the product.</p>
    <p num="p-0018">Thus, there is a need for pharmaceutical formulations of lipophilic therapeutic agents that overcome the limitations of the many known approaches.</p>
    <heading>BRIEF SUMMARY OF THE INVENTION</heading> <p num="p-0019">The present invention provides a pharmaceutical formulation that overcomes the problems associated with parenteral formulations of lipophilic drugs. The present invention provides a formulation that can be terminally sterilized, and contains little or no organic solvent such as alcohol. It has also been surprisingly discovered that the novel formulations of the present invention provide a synergistic solubilizing and antioxidative effect. Additionally, the present invention allows for the inclusion or occlusion of aseptic agents, depending on the intended use and/or handling.</p>
    <p num="p-0020">The present invention provides a pharmaceutical formulation comprising a therapeutically effective amount of (1) a lipophilic therapeutic agent, (4) a non-ionic solubilizer, (3) a lipophilic antioxidant, and (4) optionally, an agent that is an organic solvent, or a preservative (e.g., antimicrobial), or both, in an aqueous vehicle. Lipophilic therapeutic agents suitable for use in the formulations of the present invention are not particularly limited. Agents of particular interest include vitamin D compounds and analogs. By employing a lipophilic, i.e., fat-soluble, antioxidant, smaller amounts of antioxidant may be used compared to known formulations utilizing water soluble antioxidants.</p>
    <p num="p-0021">The formulations of the present invention preclude the need for high organic solvent contents, which can cause irritations in some patients. In addition, formulations of the present invention omit buffers and chelating agents. The use of buffers and chelating agents in, e.g., some prior vitamin D formulations, has been linked to the introduction of undesirable aluminum levels into the product and eventually into the patient.</p>
    <p num="p-0022">The invention also relates to methods for the treatment and/or prophylaxis of certain diseases and disorders comprising administering, e.g., parenterally, to a patient in need thereof a formulation in accordance with the present invention. For example, for formulations containing vitamin D compounds or analogs, these diseases include hyperparathyroidism, e.g., secondary hyperparathyroidsim, neoplastic diseases, such as cancers of the pancreas, breast, colon or prostate as well as other diseases of abnormal cell differentiation and/or cell proliferation such as psoriasis, and disorders of calcium metabolism such as osteomalacia.</p>
    <p num="p-0023">Other advantages and a fuller appreciation of the specific attributes of this invention will be gained upon an examination of the following detailed description of the invention, and appended claims.</p>
    <description-of-drawings> <heading>BRIEF DESCRIPTION OF THE DRAWINGS</heading> <p num="p-0024">Not applicable.</p>
    </description-of-drawings> <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p num="p-0025">The present invention provides a stable, self-preserved pharmaceutical formulation of a lipophilic therapeutic agent in aqueous vehicle utilizing a non-ionic solubilizer and lipophilic antioxidant. The formulation is suitable for parenteral administration.</p>
    <p num="p-0026">As used herein, “lipophilic” in reference to a therapeutic agent or drug is intended to mean a sparingly (or poorly, slightly, scarcely) soluble biologically active or pharmaceutically active substance or antigen-comprising material, which has a therapeutic or prophylactic effect, and has utility in the treatment or prevention of diseases or disorders affecting mammals, including humans, or in the regulation of an animal or human physiological condition. The water-solubility of lipophilic drugs, at room temperature, is typically too low to make commercially proposable, sufficiently active or advantageous any aqueous preparations containing the compound as an active ingredient. Lipophilic therapeutic agents include substances, typically compounds, with little or no water solubility. Intrinsic water solubilities (i.e., water solubility of the unionized form) for lipophilic therapeutic agents usable in-the present invention include, for example, those with a solubility of less than about 1% by weight, and typically less than about 0.1% or 0.01% by weight, or, e.g., less than about 10 μg/mL.</p>
    <p num="p-0027">Lipophilic therapeutic agents suitable for use in the formulations of the present invention are not particularly limited, as the method of the present invention is surprisingly capable of solubilizing and delivering a wide variety of lipophilic therapeutic agents. Therapeutic agents that can be utilized with the formulations of the present invention may be selected from a wide range of biologically and/or pharmacologically active substances which lack adequate solubility in aqueous systems without a solubilizing agent. Such therapeutic agents include any agents having therapeutic or other value when administered to an animal, particularly to a mammal, such as drugs, prodrugs (i.e., agents than transform into active substances), nutrients (nutraceuticals), and cosmetics (cosmeceuticals). Such therapeutic agents can be utilized in formulations in accordance with the present invention so as to yield an effective therapeutic dose, e.g., for parenteral administration. The precise biological and/or pharmacological activity of the substance is immaterial, so long as the substance can be solubilized in the present formulations.</p>
    <p num="p-0028">Specific non-limiting examples of lipophilic therapeutic agents that can be used in the formulations of the present invention include the following representative compounds, as well as their pharmaceutically acceptable salts, isomers, esters, ethers and other derivatives. These include:</p>
    <p num="p-0029">analgesics and anti-inflammatory agents, such as aloxiprin, auranofin, azapropazone, benorylate, capsaicin, celecoxib, diclofenac, diflunisal, etodolac, fenbufen, fenoprofen calcium, flurbiprofen, ibuprofen, indomethacin, ketoprofen, ketorolac, leflunomide, meclofenaminc acid, mefenamic acid, nabumetone, naproxen, oxaprozin, oxyphenbutazone, phenylbutazone, piroxicam, rofecoxib, sulindac, tetrahydrocannabinol, tramadol and tromethamine;</p>
    <p num="p-0030">anthelmintics, such as albendazole, bephenium hydroxynaphthoate, cambendazole, dichlorophen, ivermectin, mebendazole, oxamniquine, oxfendazole, oxantel embonate, praziquantel, pyrantel embonate and thiabendazole;</p>
    <p num="p-0031">anti-arrhythmic agents, such as amiodarone HCl, disopyramide, flecainide acetate and quinidine sulfate;</p>
    <p num="p-0032">anti-asthma agents, such as zileuton, zafirlukast, terbutaline sulfate, montelukast, and albuterol;</p>
    <p num="p-0033">anti-bacterial agents, such as alatrofloxacin, azithromycin, baclofen, benzathine penicillin, cinoxacin, ciprofloxacin HCl, clarithromycin, clofazimine, cloxacillin, demeclocycline, dirithromycin, doxycycline, erythromycin, ethionamide, furazolidone, grepafloxacin, imipenem, levofloxacin, lorefloxacin, moxifloxacin HCl, nalidixic acid, nitrofurantoin, norfloxacin, ofloxacin, rifampicin, rifabutine, rifapentine, sparfloxacin, spiramycin, sulphabenzamide, sulphadoxine, sulphamerazine, sulphacetamide, sulphadiazine, sulphafurazole, sulphamethoxazole, sulphapyridine, tetracycline, trimethoprim, trovafloxacin, and vancomycin;</p>
    <p num="p-0034">anti-viral agents, such as abacavir, amprenavir, delavirdine, efavirenz, indinavir, lamivudine, nelfinavir, nevirapine, ritonavir, saquinavir, and stavudine;</p>
    <p num="p-0035">anti-coagulants, such as cilostazol, clopidogrel, dicumarol, dipyridamole, nicoumalone, oprelvekin, phenindione, ticlopidine, and tirofiban;</p>
    <p num="p-0036">anti-depressants, such as amoxapine, bupropion, citalopram, clomipramine, fluoxetine HCl, maprotiline HCl, mianserin HCl, nortriptyline HCl, paroxetine HCl, sertraline HCl, trazodone HCl, trimipramine maleate, and venlafaxine HCl;</p>
    <p num="p-0037">anti-diabetic agents, such as acetohexamide, chlorpropamide, glibenclamide, gliclazide, glipizide, glimepiride, miglitol, pioglitazone, repaglinide, rosiglitazone, tolazamide, tolbutamide and troglitazone;</p>
    <p num="p-0038">anti-epileptic agents, such as beclamide, carbamazepine, clonazepam, thotoin, felbamate, fosphenytoin sodium, lamotrigine, methoin, methsuximide, methylphenobarbitone, oxcarbazepine, paramethadione, phenacemide, phenobarbitone, phenytoin, phensuximide, primidone, sulthiame, tiagabine HCl, topiramate, valproic acid, and vigabatrin;</p>
    <p num="p-0039">anti-fungal agents, such as amphotericin, butenafine HCl, butoconazole nitrate, clotrimazole, econazole nitrate, fluconazole, flucytosine, griseofulvin, itraconazole, ketoconazole, miconazole, natamycin, nystatin, sulconazole nitrate, oxiconazole, terbinafine HCl, terconazole, tioconazole and undecenoic acid;</p>
    <p num="p-0040">anti-gout agents, such as allopurinol, probenecid and sulphinpyrazone;</p>
    <p num="p-0041">anti-hypertensive agents, such as amlodipine, benidipine, benezepril, candesartan, captopril, darodipine, dilitazem HCl, diazoxide, doxazosin HCl, enalapril, eposartan, losartan mesylate, felodipine, fenoldopam, fosenopril, guanabenz acetate, irbesartan, isradipine, lisinopril, minoxidil, nicardipine HCl, nifedipine, nimodipine, nisoldipine, phenoxybenzamine HCl, prazosin HCl, quinapril, reserpine, terazosin HCl, telmisartan, and valsartan;</p>
    <p num="p-0042">anti-malarial agents, such as amodiaquine, chloroquine, chlorproguanil HCl, halofantrine HCl, mefloquine HCl, proguanil HCl, pyrimethamine and quinine sulfate;</p>
    <p num="p-0043">anti-migraine agents, such as dihydroergotamine mesylate, ergotamine tartrate, frovatriptan, methysergide maleate, naratriptan HCl, pizotifen maleate, rizatriptan benzoate, sumatriptan succinate, and zolmitriptan;</p>
    <p num="p-0044">anti-muscarinic agents, such as atropine, benzhexol HCl, biperiden, ethopropazine HCl, hyoscyamine, mepenzolate bromide, oxyphencyclimine HCl and tropicamide;</p>
    <p num="p-0045">anti-neoplastic agents and immunosuppressants, such as aminoglutethimide, amsacrine, azathioprine, bicalutamide, bisantrene, busulfan, camptothecin, capecitabine, chlorambucil, cyclosporin, dacarbazine, ellipticine, estramustine, etoposide, irinotecan, lomustine, melphalan, mercaptopurine, methotrexate, mitomycin, mitotane, mitoxantrone, mofetil mycophenolate, nilutamide, paclitaxel, procarbazine HCl, sirolimus, tacrolimus, tamoxifen citrate, teniposide, testolactone, topotecan HCl, and toremifene citrate;</p>
    <p num="p-0046">anti-protozoal agents, such as atovaquone, benznidazole, clioquinol, decoquinate, diiodohydroxyquinoline, diloxanide furoate, dinitolmide, furazolidone, metronidazole, nimorazole, nitrofurazone, ornidazole and tinidazole;</p>
    <p num="p-0047">anti-thyroid agents, such as carbimazole and propylthiouracil;</p>
    <p num="p-0048">anti-tussives, such as benzonatate;</p>
    <p num="p-0049">anxiolytics, sedatives, hypnotics and neuroleptics, such as alprazolam, amylobarbitone, barbitone, bentazepam, bromazepam, bromperidol, brotizolam, butobarbitone, carbromal, chlordiazepoxide, chlormethiazole, chlorpromazine, chlorprothixene, clonazepam, clobazam, clotiazepam, clozapine, diazepam, droperidol, ethinamate, flunanisone, flunitrazepam, triflupromazine, flupenthixol decanoate, fluphenthixol decanoate, flurazepam, gabapentin, haloperidol, lorazepam, lormetazepam, medazepam, meprobamate, mesoridazine, methaqualone, methylphenidate, midazolam, molindone, nitrazepam, olanzapine, oxazepam, pentobarbitone, perphenazine pimozide, prochlorperazine, pseudoephedrine, quetiapine, risperidone, sertindole, sulpiride, temazepam, thioridazine, triazolam, zolpidem, and zopiclone;</p>
    <p num="p-0050">β-blockers, such as acebutolol, alprenolol, atenolol, labetalol, metoprolol, nadolol, oxprenolol, pindolol and propranolol;</p>
    <p num="p-0051">cardiac inotropic agents, such as anrinone, digitoxin, digoxin, enoximone, lanatoside C and medigoxin;</p>
    <p num="p-0052">corticosteroids, such as beclomethasone, betamethasone, budesonide, cortisone acetate, desoxymethasone, dexamethasone, fludrocortisone acetate, flunisolide, fluocortolone, fluticasone propionate, hydrocortisone, methylprednisolone, prednisolone, prednisone and triamcinolone;</p>
    <p num="p-0053">diuretics, such as acetazolamide, amiloride, bendroflumethiazide, bumetanide, chlorothiazide, chlorthalidone, ethacrynic acid, frusemide, metolazone, spironolactone and triamterene;</p>
    <p num="p-0054">anti-parkinsonian agents, such as bromocriptine mesylate, lysuride maleate, pramipexole, ropinirole HCl, and tolcapone;</p>
    <p num="p-0055">gastrointestinal agents, such as bisacodyl, cimetidine, cisapride, diphenoxylate HCl, domperidone, famotidine, lanosprazole, loperamide, mesalazine, nizatidine, omeprazole, ondansetron HCl, rabeprazole sodium, ranitidine HCl and sulphasalazine;</p>
    <p num="p-0056">histamine H<sub>1 </sub>and H<sub>2</sub>-receptor antagonists, such as acrivastine, astemizole, chlorpheniramine, cinnarizine, cetrizine, clemastine fumarate, cyclizine, cyproheptadine HCl, dexchlorpheniramine, dimenhydrinate, fexofenadine, flunarizine HCl, loratadine, meclizine HCl, oxatomide, and terfenadine;</p>
    <p num="p-0057">keratolytics, such as acetretin, calciprotriene, calcifediol, calcitriol, cholecalciferol, ergocalciferol, etretinate, retinoids, targretin, and tazarotene;</p>
    <p num="p-0058">lipid regulating agents, such as atorvastatin, bezafibrate, cerivastatin, ciprofibrate, clofibrate, fenofibrate, fluvastatin, gemfibrozil, pravastatin, probucol, and simvastatin;</p>
    <p num="p-0059">muscle relaxants, such as dantrolene sodium and tizanidine HCl;</p>
    <p num="p-0060">nitrates and other anti-anginal agents, such as amyl nitrate, glyceryl trinitrate, isosorbide dinitrate, isosorbide mononitrate and pentaerythritol tetranitrate;</p>
    <p num="p-0061">nutritional agents and fat-soluble vitamins, such as calcitriol, carotenes, dihydrotachysterol, essential fatty acids, non-essential fatty acids, phytonadiol, vitamin A, vitamin B<sub>2</sub>, vitamin D, vitamin E and vitamin K;</p>
    <p num="p-0062">opioid analgesics, such as codeine, dextropropoxyphene, diamorphine, dihydrocodeine, fentanyl, meptazinol, methadone, morphine, nalbuphine and pentazocine;</p>
    <p num="p-0063">sex hormones, such as clomiphene citrate, cortisone acetate, danazol, dehydroepiandrosterone, ethynyl estradiol, finasteride, fludrocortisone, fluoxymesterone, medroxyprogesterone acetate, megestrol acetate, mestranol, methyltestosterone, norethisterone, norgestrel, oestradiol, conjugated estrogens, progesterone, rimexolone, stanozolol, stilbestrol, testosterone and tibolone;</p>
    <p num="p-0064">stimulants, such as amphetamine, dexamphetamine, dexfenfluramine, fenfluramine and mazindol;</p>
    <p num="p-0065">and others, e.g., erectile dysfunction improvement agents, anti-osteoporosis agents, anti-obesity agents, cognition enhancers, anti-urinary incontinence agents, anti-benign prostate hypertrophy agents, such as becaplermin, donepezil HCl, L-thryroxine, methoxsalen, verteporfin, physostigmine, pyridostigmine, raloxifene HCl, sibutramine HCl, sildenafil citrate, tacrine, tamsulosin HCl, and tolterodine.</p>
    <p num="p-0066">It should be appreciated that this listing of lipophilic therapeutic agents and their therapeutic classes is merely illustrative. Indeed, a particular feature, and surprising advantage, of the formulations of the present invention is the ability of the present formulations to solubilize and deliver a broad range of lipophilic therapeutic agents, regardless of functional class. Of course, mixtures of lipophilic therapeutic agents may also be used where desired.</p>
    <p num="p-0067">Examples of lipophilic agents of particular interest include active vitamin D compounds. As used herein, the term “activated vitamin D” or “active vitamin D” is intended to include any biologically active vitamin D compound, including a pro-drug (or pro-hormone), a precursor, a metabolite or an analog, in any stage of its metabolism. It is known that vitamin D compounds display a variety of biological activities, e.g., in calcium and phosphate metabolism (see, e.g., U.S. Pat. No. 5,104,864), as an antineoplastic agent (see, e.g., U.S. Pat. No. 5,763,429), and as an anti-hyperparthyroid agent (see, e.g., U.S. Pat. No. 5,602,116), and it is contemplated that any of the biologically active forms of vitamin D can be used in the formulations in accordance with the present invention. Generally, an active vitamin D compound or analog is hydroxylated in at least the C-1, C-24 or C-25 position of the molecule, and either the compound itself or its metabolite binds to the vitamin D receptor (VDR). Pro-drugs, for example, include vitamin D compounds that are hydroxylated in the C-1. Such compounds undergo further hydroxylation in vivo and their metabolites bind the VDR.</p>
    <p num="p-0068">Precursors include previtamins, such as 1α-hydroxyprevitamin D<sub>2</sub>, 1α,24-dihydroxyprevitamin D<sub>2</sub>, 1α,25-dihydroxyprevitamin D<sub>2</sub>, 24-hydroxyprevitamin D<sub>2</sub>, 1α-hydroxyprevitamin D<sub>3 </sub>and 1α,25-dihydroxyprevitamin D<sub>3</sub>, which are thermal isomeric forms of the vitamin forms. Metabolites generally include compounds or analogs that have undergone further metabolic processing, e.g., hydroxylation.</p>
    <p num="p-0069">Examples of vitamin D compounds suitable for formulations of the present invention include, without limitation, 1α,24-dihydroxyvitamin D<sub>2</sub>, 1α,2-dihydroxyvitamin D<sub>4</sub>, 1α,24-dihydroxyvitamin D<sub>2</sub>, 1α,25-dihydroxyvitamin D<sub>3 </sub>(calcitriol), 1α hydroxyvitamin D<sub>3 </sub>(α-calcidol) 1α,25-dihydroxyvitamin D<sub>2</sub>, 1α,25-dihydroxyvitamin D<sub>4</sub>, and 1α,24,25-dihydroxyvitamin D<sub>2</sub>, seocalcitol (EB-1089), calcipotriol, 22-oxacalcitriol (maxacalcitol), fluorinated compounds such as falecalcitriol, and 19-nor compounds such as paricalcitol. Among those compounds having a chiral center, e.g., in the sidechain, such as at C-24, it is understood that both epimers (e.g., R and S) and the epimeric mixture are within the scope of the present invention.</p>
    <p num="p-0070">It also is understood that any numerical value recited herein includes all values from the lower value to the upper value. For example, if a concentration range is stated as 1% to 50%, it is intended that values such as 2% to 40%, 10% to 30%, or 1% to 3%, etc., are expressly enumerated in this specification. These are only examples of what is specifically intended, and all possible combinations of numerical values between the lowest value and the highest value enumerated are to be considered to be expressly stated in this application.</p>
    <p num="p-0071">The amount of selected therapeutic is not critical to the present invention and may be varied to achieve the desired therapeutic response for a particular patient. The amount of active therapeutic agent in the formulations of the invention will be dependent, in part, on the solubility of the specific surfactant used and its intended use. Those skilled in the arts can adjust the ratios without undue experimentation. The selected dosage also will depend on the activity of the specific therapeutic, the route of administration, the severity of the condition being treated and the condition and history of the specific patient. For example, a therapeutic dose for vitamin D-type compounds may range between about 2 μg and about 100 μg/dose.</p>
    <p num="p-0072">Suitable solubilizing agents for the formulations of the present invention include nonionic solubilizers. A non-ionic solubilizer is one where the hydrophilic part of the solubilizer carries no charge but derives its water solubility from highly polar groups such as hydroxyl or polyoxyethylene groups. Some surfactants known for use in the pharmaceutical field also have a solubilizing function.</p>
    <p num="p-0073">Solubilizers generally include, but are not limited to, the polyoxyalkylenes dextrans, fatty acid esters of saccharose, fatty alcohol ethers of oligoglucosides (e.g., the akylpolyglucosides such as TRITON™), fatty acid esters of glycerol (e.g., glycerol mono/distearate or glycerol monolaurate), and polyoxyethylene type compounds (e.g., POE, PEG, PEO, SOLUTOL™ CREOMOPHOR™S, MACROGOL, CARBOWAX, POLYOXYL). The latter also include polyethoxylated fatty acid esters of sorbitan (e.g., polysorbates, such as TWEEN™s, SPAN™s), fatty acid esters of poly(ethylene oxide) (e.g., polyoxyethylene stearates), fatty alcohol ethers of poly(ethylene oxide) (e.g., polyoxyethylated lauryl ether), alkylphenol ethers of poty(ethylene oxide) (e.g., polyethoxylated octylphenol), polyoxyethylene-polyoxypropylene block copolymers (also known as poloxamers, such as “Pluronic”), and ethoxylated fats and oils (e.g., ethoxylated castor oil, or polyoxyethylated castor oil, also known as polyethylene glycol-glyceryl triricinoleate). Mixtures of solublilizers are also within the scope of the invention. Such mixtures are readily available from standard commerical sources. Solubilizers of particular interest include polysorbates, e.g. TWEEN™. Amounts of such solubilizer present in the formulations of the present invention include from about 0.05% to about 5% w/w.</p>
    <p num="p-0074">Suitable lipophilic antioxidants include, but are not limited to, butylated hydroxytoluene (BHT), lipoic acid, lycopene, lutein, lycophyll, xanthophyll, carotene, zeaxanthin or vitamin E and/or esters thereof. The lipophilic antioxidants are present in very small but effective amounts, e.g., about 20 to about 2000 ppm.</p>
    <p num="p-0075">If desired, formulations of the present invention can optionally include additional agents to enhance the solubility of the lipophilic therapeutic agent in the carrier system. Examples of such optional agents include organics solvents, preservatives or both. Such agents include alcohols and polyols, such as ethanol, benzyl alcohol, chlorobutanol, isopropanol, butanol, ethylene glycol, propylene glycol, butanediols, glycerol, pentaerythritol, sorbitol, mannitol, transcutol, dimethyl isosorbide, polyethylene glycol, polypropylene glycol, polyvinylalcohol, hydroxypropyl methylcellulose and other cellulose derivatives, cyclodextrins and cyclodextrin derivatives. Amounts of optional agents include 0% to about 30% w/w, e.g., organic solvent. A useful range is 0% to about 10% w/w, and a particularly useful range is about 1% to about 3%.</p>
    <p num="p-0076">Accordingly, a formulation in accordance with the present invention includes a lipophilic drug agent (e.g., a drug agent with a solubility in water of &lt;10 μg/mL), about 0.05% to about 5% w/w of a non-ionic solubilizer, about 20 to about 2000 ppm lipophilic antioxidant, and 0% to about 30% w/w optional agent. A particular formulation for treating secondary hyperparathyroidism includes 2–6 μg/mL 1α-hydroxyvitamin D<sub>2 </sub>(doxercalciferol), 2.5% w/w benzyl alcohol, 0.5%–2.5% w/w TWEEN™-20, and 20 ppm BHT. The amount of optional agent, e.g., benzyl alcohol or ethanol, may range from 0 to 30% w/w; a highly useful range comprises 1% to 3% w/w. With a vitamin D formulation (e.g., a doxercalciferol formulation), a most useful amount of optional agent comprises 2.5% w/w.</p>
    <p num="p-0077">A pharmaceutical formulation in accordance with the present invention comprises an aqueous vehicle. The aqueous vehicle contains, of course, water, but it may furthermore also contain pH adjusting agents, stabilizing agents, solubilizing agent (see, hereinabove), isotonic adjusting agents, and solvents (e.g. organic solvents; as discussed above). A formulation in accordance with the present invention precludes the need for high organic solvent which can cause irritation in some patients. In some cases, however, it may be appropriate to include an organic solvent or co-solvents. The amount of water in a formulation in accordance with the present invention is normally at least about from about 50% to about 99% w/w.</p>
    <p num="p-0078">For the pharmaceutical formulations of the present invention, the intended route of administration is suitably parenteral, i.e., for use by injection into, e.g., an animal or human body. Such route includes intravenous, intramuscular and subcutaneous administration, the intravenous route being especially suitable for the formulations of the present invention for use in connection with, e.g., secondary hyperparathyroidism or neoplastic disorders.</p>
    <p num="p-0079">However, whenever relevant, formulations in accordance with the present invention may also be suitable for use by other administration routes such as, e.g., the oral route, the topical route or the nasal route. In such cases, a person skilled in the art can make any necessary adjustments with respect to the concentration of the active substance and with respect to the other ingredients included in the formulation.</p>
    <p num="p-0080">A formulation in accordance with the present invention is normally presented as an aqueous solution. However, in certain cases such as, e.g., in connection with the administration of a formulation by the topical or oral route, a formulation in accordance with the present invention may include a liquid composition which may be presented in the form of a solution or a gel.</p>
    <p num="p-0081">Pharmaceutical formulations may be readily prepared by using pharmacopoeia grade reagents in which the reagents are made up in stock solutions from which the resulting solutions at the appropriate concentrations can be made. Once the appropriate amounts of stock solution and combined, it is often desirable to stir the reagents for several minutes under nitrogen gas gently blown over the top of the mixture, i.e., a nitrogen gas overlay. Degassed Water for Injection is then added to bring the desired final volume, and stirring under nitrogen gas continued for another several minutes.</p>
    <p num="p-0082">A pharmaceutical formulation in accordance with the present invention containing a vitamin D compound or a vitamin D analogue like those substances described above, is suitable for use in the treatment and/or prophylaxis of (i) diseases or conditions characterized by abnormal cell differentiation and/or cell hyperproliferation such as, e.g., psoriasis and other disturbances of keratinisation, neoplastic diseases and cancers, such as pancreas, breast, colon and prostate cancers as well as skin cancer; (ii) diseases of, or imbalance in, the immune system, such as host-versus-graft and graft-versus-host reaction and transplant rejection, and auto-immune diseases such as discoid and systemic lupus erythematosus, diabetes mellitus and chronic dermatoses of auto-immune type, e.g., scleroderma and pemphigus vulgaris; (iii) inflammatory diseases such as rheumatoid arthritis as well as in the treatment and/or prophylaxis of a number of (iv) other diseases or disease states, including hyperparathyroidism, particularly secondary hyperparathyroidism associated with renal failure, and in promoting (v) osteogenesis and treating/preventing bone loss as in osteoporosis and osteosmalacia. (For use of vitamin D compounds for treatment and prophylaxis, see, e.g., U.S. Pat. Nos. 5,9722,917; 5,798,345; 5,763,428; 5,602,116; 5,869,386; 5,104,864; 5,403,831; 5,880,114; 5,561,123. The vitamin D formulations in accordance with the present invention are especially suited for treatment of cell hyperproliferative disorders; disorders of the calcium metabolism, such as osteomalacia; or neoplastic diseases, such as cancers of the pancreas, breast, colon or prostate. The method of treatment comprises treating the cells and/or administering to a patient in need thereof a formulation in accordance with the present invention in an amount that is effective to amelariate or prevent the disease or disorder. For example, in the treatment of hyperproliferative or neoplastic diseases, an effective amount is, e.g., a growth-inhibiting amount. Daily dosages as well as episodic doses, e.g., once per week to three times per week, are contemplated.</p>
    <p num="p-0083">Additionally, as described hereinabove, vitamin D compounds in accordance with the present invention include prodrugs, i.e., drugs that require further metabolic processing in vivo, e.g., additional hydroxlation. Such prodrugs of vitamin D compounds that have been found to be effective therapeutic agents are generally less reactive than, e.g., the dihydroxy natural hormone, 1α,25-dihydroxyvitamin D<sub>3</sub>. These compounds may offer further advantage for use in formulations.</p>
    <p num="p-0084">In addition, formulations of the current invention may be terminally sterilized by means of e.g., autoclaving.</p>
    <p num="p-0085">The present invention is further explained by the following examples which should not be construed by way of limiting the scope of the present invention.</p>
    <heading>Preparation of Stock Solutions</heading> <heading>EXAMPLE 1</heading> <heading>Doxercalciferol (1α-hydroxyvitamin D<sub>2</sub>) Stock Solution</heading> <p num="p-0086">12.558 mg of doxercalciferol was weighed and transferred to a 10-mL volumetric flask. The solid was diluted to volume with ethanol and the flask was vigorously shaken to dissolve the solid.</p>
    <heading>EXAMPLE 2</heading> <heading>Butylated Hydroxytoluene (BHT) Stock Solution</heading> <p num="p-0087">2.22 g BHT was transferred to a 100-mL volumetric flask. The solid was diluted to volume with ethanol and the flask was vigorously shaken to dissolve the solid.</p>
    <heading>EXAMPLE 3</heading> <heading>10% TWEEN™-20</heading> <p num="p-0088">100 g TWEEN™-20KR was transferred to a 1-L volumetric flask and diluted to volume with degassed Water for Injection. A magnetic stir bar was added and the mixture stirred to mix.</p>
    <heading>Formulations</heading> <heading>EXAMPLE 4</heading> <heading>Doxercalciferol Formulations</heading> <p num="p-0089">The general procedure for preparing doxercalciferol formulations was as follows. To a glass formulation vessel was added Doxercalciferol Stock Solution, 10% TWEEN™-20, BHT Stock Solution, and ethanol, in the order listed. Nitrogen gas was gently blown over the top of the mixture. A stir bar was added to the mixture and stirred for not less than 20 minutes while continuing the nitrogen gas overlay. Degassed Water for Injection was added to bring the final volume to one liter. The mixture was stirred for not less than 20 minutes while continuing the nitrogen gas overlay. The volumes of each component used in preparing the formulations are listed in the Table 1 below.</p>
    <p num="p-0090">
      <tables id="TABLE-US-00001" num="00001"> <table frame="none" colsep="0" rowsep="0" class="description-table"> <tgroup align="left" colsep="0" rowsep="0" cols="1"> <colspec colname="1" colwidth="217pt" align="center"> </colspec> <thead> <tr class="description-tr"> <td namest="1" nameend="1" rowsep="1" class="description-td" colspan="1">TABLE 1</td>
              </tr> </thead> <tbody valign="top"> <tr class="description-tr"> <td namest="1" nameend="1" align="center" rowsep="1" class="description-td" colspan="1"> </td>
              </tr> <tr class="description-tr"> <td class="description-td">Preparation of Doxercalciferol Formulations</td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="1" colwidth="56pt" align="center"> </colspec> <colspec colname="2" colwidth="42pt" align="center"> </colspec> <colspec colname="3" colwidth="42pt" align="center"> </colspec> <colspec colname="4" colwidth="28pt" align="center"> </colspec> <colspec colname="5" colwidth="49pt" align="center"> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">Doxercalciferol</td>
                <td class="description-td">Tween ™-20</td>
                <td class="description-td">BHT Stock</td>
                <td class="description-td">Ethanol</td>
                <td class="description-td">Water for</td>
              </tr> <tr class="description-tr"> <td class="description-td">Stock (mL)</td>
                <td class="description-td">Stock (mL)</td>
                <td class="description-td">(mL)</td>
                <td class="description-td">(mL)</td>
                <td class="description-td">Injection (mL)</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> <tgroup align="left" colsep="0" rowsep="0" cols="5"> <colspec colname="1" colwidth="56pt" align="char" char="."> </colspec> <colspec colname="2" colwidth="42pt" align="char" char="."> </colspec> <colspec colname="3" colwidth="42pt" align="char" char="."> </colspec> <colspec colname="4" colwidth="28pt" align="char" char="."> </colspec> <colspec colname="5" colwidth="49pt" align="char" char="."> </colspec> <tbody valign="top"> <tr class="description-tr"> <td class="description-td">2.0</td>
                <td class="description-td">50</td>
                <td class="description-td">1.0</td>
                <td class="description-td">27</td>
                <td class="description-td">920</td>
              </tr> <tr class="description-tr"> <td class="description-td">6.0</td>
                <td class="description-td">250</td>
                <td class="description-td">1.0</td>
                <td class="description-td">23</td>
                <td class="description-td">720</td>
              </tr> <tr class="description-tr"> <td namest="1" nameend="5" align="center" rowsep="1" class="description-td" colspan="5"> </td>
              </tr> </tbody> </tgroup> </table> </tables> </p>
    <heading>Use of Formulations</heading> <heading>EXAMPLE 5</heading> <heading>Double-Blind Study in End Stage Renal Disease (ESRD) Patients Exhibiting Secondary Hyperparathyroidism</heading> <p num="p-0091">Up to 120 ESRD (End Stage Renal Disease) patients undergoing chronic hemodialysis are studied in a multicenter, double-blind, placebo-controlled study based in two major U.S. metropolitan areas. The selected patients reside in two major metropolitan areas within the continental U.S., have ages between 20 and 75 years and have a history of secondary hyperparathyroidism. They have been on hemodialysis for at least four months, have a normal (or near normal) serum albumin, and have controlled serum phosphorus (often by using oral calcium phosphate binders).</p>
    <p num="p-0092">On admission to the study, each patient is assigned at random to one of two treatment groups. One of these groups receives two consecutive 12-week courses of therapy with 1α-OH-vitamin D<sub>2 </sub>(doxercalciferol); the other receives a 12-week course of therapy with 1α-OH-vitamin D<sub>2 </sub>followed, without interruption, by a 12-week course of placebo therapy. Each patient discontinues any 1, α,25-(OH)<sub>2</sub>-vitamin D<sub>3 </sub>therapy for eight weeks prior to initiating 1α-OH-vitamin D<sub>2 </sub>therapy (daily dose of 4 μg doxercalciferol, formulated with 2.5% w/w benzyl alcohol, 0.5%–2.5% w/w TWEEN™-20, and 20 ppm BHT). Throughout this eight-week washout (or control) period and the two subsequent 12-week treatment periods, patients are monitored weekly for serum calcium and phosphorus. Serum intact PTH is monitored weekly or biweekly, and bone-specific serum markers, serum vitamin D metabolites, serum albumin, blood chemistries, hemoglobin and hematocrit are monitored at selected intervals.</p>
    <p num="p-0093">During the study, patients undergo routine hemodialysis (three times per week) using a 1.24 mM calcium dialysate and ingest calcium phosphate binders (such as calcium carbonate or calcium acetate) in an amount sufficient to keep serum phosphate controlled (6.9 mg/dL). Patients who develop persistent mild hypercalcemia or mild hyperphosphatemia during the treatment periods reduce their 1α-OH-vitamin D<sub>2 </sub>to 4 μg three times per week (or lower). Patients who develop marked hypercalcemia or marked hyperphosphatemia immediately suspend treatment. Such patients are monitored at twice weekly intervals until the serum calcium or phosphorus is normalized, and resume 1α-OH-vitamin D<sub>2 </sub>dosing at a rate which is 4 μg three times per week (or lower).</p>
    <p num="p-0094">During the eight-week washout period, the mean serum level of PTH increases progressively and significantly. After initiation of 1α-OH-vitamin D<sub>2 </sub>dosing, mean serum PTH decreases significantly to less than 50% of pretreatment levels. Due to this drop in serum PTH, some patients need to reduce their dosage of 1α-OH-vitamin D<sub>2 </sub>to 4 μg three times per week (or to even lower levels) to prevent excessive suppression of serum PTH. In such patients, exhibiting excessive suppression of serum PTH, transient mild hypercalcemia is observed, which is corrected by appropriate reductions in 1α-OH-vitamin D<sub>2 </sub>dosages.</p>
    <p num="p-0095">At the end of the first 12-week treatment period, mean serum PTH is in the desired range of 130 to 240 μg/mL and serum levels of calcium and phosphorus are normal or near normal for end stage renal disease patients. At the end of the second 12-week treatment period (during which time 1α-OH-vitamin D<sub>2 </sub>treatment is suspended and replaced by placebo therapy), mean serum PTH values markedly increase, reaching pretreatment levels. This study demonstrates that: (1) 1α-OH-vitamin D<sub>2 </sub>is effective in reducing serum PTH levels, and (2) 1α-OH-vitamin D<sub>2 </sub>is safer than currently used therapies, despite its higher dosages and concurrent use of high levels of oral calcium phosphate binder.</p>
    <heading>EXAMPLE 6</heading> <heading>Open Label Study of Elderly Subjects with Elevated Blood PTH from Secondary Hyperparathyroidism</heading> <p num="p-0096">Thirty elderly subjects with secondary hyperparathyroidism are enrolled in an open label study. The selected subjects have ages between 60 and 100 years and have elevated serum PTH levels (greater than the upper limit of young normal range). Subjects also have femoral neck osteopenia (femoral neck bone mineral density of 0.70 μg/cm<sup>2</sup>).</p>
    <p num="p-0097">Subjects are requested to keep a diet providing approximately 500 mg calcium per day without the use of calcium supplements. For a twelve week treatment period, subjects self-administer orally 2.5 μg/day 1α-OH-vitamin D<sub>2</sub>.(i.e., 2.5 μg doxercalciferol, 2.5% w/w benzyl alcohol, 0.5%–2.5% w/w TWEEN™-20, and 20 ppm BHT) At regular intervals throughout the treatment period, subjects are monitored for serum PTH levels, serum calcium and phosphorus, and urine calcium and phosphorus levels. Efficacy is evaluated by pre- and post-treatment comparisons of serum PTH levels. Safety is evaluated by serum and urine calcium and phosphorus values.</p>
    <p num="p-0098">The administration of 1α-OH-vitamin D<sub>2 </sub>is shown to significantly reduce PTH levels with an insignificant incidence of hypercalcemia, hyperphosphatemia, hypercalciuria and hyperphosphaturia.</p>
    <heading>EXAMPLE 7</heading> <heading>Clinical Studies of 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>in Treatment of Prostate Cancer</heading> <p num="p-0099">Patients with advanced androgen-independent prostate cancer participate in an open-labeled study of 1α,24-(OH)<sub>2</sub>D<sub>2</sub>. Qualified patients are at least 40 years old, exhibit histologic evidence of adenocarcinoma of the prostate, and present with progressive disease which had previously responded to hormonal intervention(s). On admission to the study, patients begin a course of therapy with intravenous 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>lasting 26 weeks, while discontinuing any previous use of calcium supplements, vitamin D supplements, and vitamin D hormone replacement therapies. During treatment, the patients are monitored at regular intervals for: (1) hypercalcemia, hyperphosphatemia, hypercalciuria, hyperphosphaturia and other toxicity; (2) evidence of changes in the progression of metastatic disease; and (3) compliance with the prescribed test drug dosage.</p>
    <p num="p-0100">The study is conducted in two phases. During the first phase, the maximal tolerated dosage (MTD) of daily 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>is determined by administering progressively higher dosages to successive groups of patients. All doses are administered in the morning before breakfast. The first group of patients is treated with 25.0 μg of 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>(formulated with 2.5% w/w benzyl alcohol, 0.5%–2.5% w/w TWEEN™-20, and 20 ppm BHT). Subsequent groups of patients are treated with 50.0, 75.0 and 100.0 μg/day. Dosing is continued uninterrupted for the duration of the study unless serum calcium exceeds 11.6 mg/dL, or other toxicity of grade 3 or 4 is observed, in which case dosing is held in abeyance until resolution of the observed toxic effect(s) and then resumed at a level which has been decreased by 10.0 μg.</p>
    <p num="p-0101">Results from the first phase of the study show that the MTD for 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>is above 20.0 μg/day, a level which is 10- to 40-fold higher than can be achieved with 1α,25-(OH)<sub>2</sub>D<sub>2</sub>. Analysis of blood samples collected at regular intervals from the participating patients reveal that the levels of circulating 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>increase proportionately with the dosage administered, rising to maximum levels well above 100 pg/mL at the highest dosages, and that circulating levels of 1α,25-(OH)<sub>2</sub>D<sub>2 </sub>are suppressed, often to undetectable levels. Serum and urine calcium are elevated in a dose responsive manner. Patients treated with the MTD of 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>for at least six months report that bone pain associated with metastatic disease is significantly diminished.</p>
    <p num="p-0102">During the second phase, patients are treated with 1α,24-(OH)<sub>2</sub>D<sub>2 </sub>for 24 months at 0.5 and 1.0 times the MTD. After one and two years of treatment, CAT scans, X-rays and bone scans used for evaluating the progression of metastatic disease show stable disease or partial remission in many patients treated at the lower dosage, and stable disease and partial or complete remission in many patients treated at the higher dosage.</p>
    <heading>EXAMPLE 8</heading> <heading>1α-(OH)D<sub>2 </sub> </heading> <p num="p-0103">The study of Example 7 is repeated for the active vitamin D compound, 1α-(OH)D<sub>2 </sub>(formulated with 2.5% w/w benzyl alcohol, 0.5%–2.5% w/w TWEEN™-20, and 20 ppm BHT). The results of the phase one study indicate that patients treated with the MTD of 1α-(OH)D<sub>2 </sub>for at least six months report that bone pain associated with metastatic disease is significantly diminished. The results of the phase two study indicate that after two years, CAT scans, X-rays and bone scans used for evaluating the progression of metastatic disease show stable disease or partial remission in many patients treated at the lower dosage, and stable disease and partial or complete remission in many patients treated at the higher dosage. In summary, the present invention provides an improved formulation for lipophilic drug agents that are only slightly soluble in an aqueous vehicle. The formulation in addition to the lipophilic drug agent includes a lipophilic antioxidant, a non-ionic solubilizer or surfactant, and optionally, an agent which is an organic solvent/ preservative.</p>
    <p num="p-0104">All patents, publications and references cited herein are hereby fully incorporated by reference. In the case of conflict between the present disclosure and the incorporated patents, publications and references, the present disclosure should control.</p>
    <p num="p-0105">While the present invention has now been described and exemplified with some specificity, those skilled in the art will appreciate the various modifications, including variations, additions, and omissions that may be made in what has been described. Accordingly, it is intended that these modifications also be encompassed by the present invention and that the scope of the present invention be limited solely by the broadest interpretation that lawfully can be accorded the appended claims.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US2383446">US2383446</a></td><td class="patent-data-table-td patent-date-value">Jun 4, 1941</td><td class="patent-data-table-td patent-date-value">Aug 28, 1945</td><td class="patent-data-table-td ">Du Pont</td><td class="patent-data-table-td ">Antirachitic materials and processes for their production</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3697559">US3697559</a></td><td class="patent-data-table-td patent-date-value">Feb 25, 1971</td><td class="patent-data-table-td patent-date-value">Oct 10, 1972</td><td class="patent-data-table-td ">Wisconsin Alumni Res Found</td><td class="patent-data-table-td ">1,25-dihydroxycholecalciferol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3741996">US3741996</a></td><td class="patent-data-table-td patent-date-value">Dec 2, 1971</td><td class="patent-data-table-td patent-date-value">Jun 26, 1973</td><td class="patent-data-table-td ">Wisconsin Alumni Res Found</td><td class="patent-data-table-td ">1{60 -hydroxycholecalciferol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3907843">US3907843</a></td><td class="patent-data-table-td patent-date-value">Jun 14, 1974</td><td class="patent-data-table-td patent-date-value">Sep 23, 1975</td><td class="patent-data-table-td ">Wisconsin Alumni Res Found</td><td class="patent-data-table-td ">1{60 -Hydroxyergocalciferol and processes for preparing same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US3932634">US3932634</a></td><td class="patent-data-table-td patent-date-value">Dec 10, 1974</td><td class="patent-data-table-td patent-date-value">Jan 13, 1976</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">High potency vitamin water dispersible formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4075333">US4075333</a></td><td class="patent-data-table-td patent-date-value">Aug 20, 1975</td><td class="patent-data-table-td patent-date-value">Feb 21, 1978</td><td class="patent-data-table-td ">Hoffmann-La Roche, Inc.</td><td class="patent-data-table-td ">Stable injectable vitamin compositions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4160803">US4160803</a></td><td class="patent-data-table-td patent-date-value">Mar 23, 1978</td><td class="patent-data-table-td patent-date-value">Jul 10, 1979</td><td class="patent-data-table-td ">Corning Glass Works</td><td class="patent-data-table-td ">Modular structure adaptable for shipping</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4195027">US4195027</a></td><td class="patent-data-table-td patent-date-value">Jun 12, 1978</td><td class="patent-data-table-td patent-date-value">Mar 25, 1980</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Process for preparing 1α-hydroxylated compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4202829">US4202829</a></td><td class="patent-data-table-td patent-date-value">Dec 13, 1978</td><td class="patent-data-table-td patent-date-value">May 13, 1980</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Process for preparing 1α-hydroxylated compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4225596">US4225596</a></td><td class="patent-data-table-td patent-date-value">Oct 13, 1978</td><td class="patent-data-table-td patent-date-value">Sep 30, 1980</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Method for treating calcium imbalance and improving calcium absorption in mammals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4234495">US4234495</a></td><td class="patent-data-table-td patent-date-value">Sep 10, 1979</td><td class="patent-data-table-td patent-date-value">Nov 18, 1980</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Process for preparing 1α-hydroxyvitamin D compounds from 1α-hydroxy-3,5-cyclovitamin D compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4260549">US4260549</a></td><td class="patent-data-table-td patent-date-value">May 21, 1979</td><td class="patent-data-table-td patent-date-value">Apr 7, 1981</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Vitamin d derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4308264">US4308264</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 1981</td><td class="patent-data-table-td patent-date-value">Dec 29, 1981</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Prevention of hydocalcemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4362710">US4362710</a></td><td class="patent-data-table-td patent-date-value">Jun 26, 1981</td><td class="patent-data-table-td patent-date-value">Dec 7, 1982</td><td class="patent-data-table-td ">Nissan Gosei Kogyo Co., Ltd.</td><td class="patent-data-table-td ">Feeds for baby pigs, process for preparing the same and method of breeding baby pigs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4364941">US4364941</a></td><td class="patent-data-table-td patent-date-value">Aug 31, 1981</td><td class="patent-data-table-td patent-date-value">Dec 21, 1982</td><td class="patent-data-table-td ">Teijin Limited</td><td class="patent-data-table-td ">Analogs of vitamin d3</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4391802">US4391802</a></td><td class="patent-data-table-td patent-date-value">Mar 9, 1982</td><td class="patent-data-table-td patent-date-value">Jul 5, 1983</td><td class="patent-data-table-td ">Chugai Seiyaku Kabushiki Kaisha</td><td class="patent-data-table-td ">1-hydroxy vitamin d derivative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4508651">US4508651</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 1983</td><td class="patent-data-table-td patent-date-value">Apr 2, 1985</td><td class="patent-data-table-td ">Hoffmann-La Roche Inc.</td><td class="patent-data-table-td ">Synthesis of 1α,25-dihydroxyergocalciferol</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4554106">US4554106</a></td><td class="patent-data-table-td patent-date-value">Nov 1, 1984</td><td class="patent-data-table-td patent-date-value">Nov 19, 1985</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Method for preparing 1α-hydroxyvitamin D compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4555364">US4555364</a></td><td class="patent-data-table-td patent-date-value">Nov 1, 1984</td><td class="patent-data-table-td patent-date-value">Nov 26, 1985</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Method for preparing 1-hydroxyvitamin D compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4588716">US4588716</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 1985</td><td class="patent-data-table-td patent-date-value">May 13, 1986</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Method for treating metabolic bone disease in mammals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4661294">US4661294</a></td><td class="patent-data-table-td patent-date-value">Mar 18, 1985</td><td class="patent-data-table-td patent-date-value">Apr 28, 1987</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Controlling calcium and phosphorus homeostasis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4689180">US4689180</a></td><td class="patent-data-table-td patent-date-value">Nov 4, 1985</td><td class="patent-data-table-td patent-date-value">Aug 25, 1987</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">1α,25-dihydroxy-22Z-dehydroxyvitamin D compound</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4698328">US4698328</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 1986</td><td class="patent-data-table-td patent-date-value">Oct 6, 1987</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Method of increasing bone mass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4717721">US4717721</a></td><td class="patent-data-table-td patent-date-value">May 30, 1985</td><td class="patent-data-table-td patent-date-value">Jan 5, 1988</td><td class="patent-data-table-td ">Howard W. Bremer</td><td class="patent-data-table-td ">Leukemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4727064">US4727064</a></td><td class="patent-data-table-td patent-date-value">May 29, 1985</td><td class="patent-data-table-td patent-date-value">Feb 23, 1988</td><td class="patent-data-table-td ">The United States Of America As Represented By The Department Of Health And Human Services</td><td class="patent-data-table-td ">Complexing low water solubility drug with water-soluble mixture</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4784845">US4784845</a></td><td class="patent-data-table-td patent-date-value">Sep 16, 1985</td><td class="patent-data-table-td patent-date-value">Nov 15, 1988</td><td class="patent-data-table-td ">American Cyanamid Company</td><td class="patent-data-table-td ">Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4816247">US4816247</a></td><td class="patent-data-table-td patent-date-value">Sep 11, 1985</td><td class="patent-data-table-td patent-date-value">Mar 28, 1989</td><td class="patent-data-table-td ">American Cyanamid Company</td><td class="patent-data-table-td ">For injections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4833125">US4833125</a></td><td class="patent-data-table-td patent-date-value">May 21, 1987</td><td class="patent-data-table-td patent-date-value">May 23, 1989</td><td class="patent-data-table-td ">The General Hospital Corporation</td><td class="patent-data-table-td ">Method of increasing bone mass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4866048">US4866048</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 1986</td><td class="patent-data-table-td patent-date-value">Sep 12, 1989</td><td class="patent-data-table-td ">Leo Pharmaceutical Products Ltd.</td><td class="patent-data-table-td ">Novel vitamin D analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4877778">US4877778</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 1987</td><td class="patent-data-table-td patent-date-value">Oct 31, 1989</td><td class="patent-data-table-td ">The Children&#39;s Medical Center Corporation</td><td class="patent-data-table-td ">Injecting water soluble 2-hydroxypropyl-b-cyclodextrin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4902481">US4902481</a></td><td class="patent-data-table-td patent-date-value">Dec 11, 1987</td><td class="patent-data-table-td patent-date-value">Feb 20, 1990</td><td class="patent-data-table-td ">Millipore Corporation</td><td class="patent-data-table-td ">Multi-well filtration test apparatus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4948788">US4948788</a></td><td class="patent-data-table-td patent-date-value">Sep 5, 1986</td><td class="patent-data-table-td patent-date-value">Aug 14, 1990</td><td class="patent-data-table-td ">Teijin Limited</td><td class="patent-data-table-td ">Freeze dried active material and an excipient; heat resistance photostability; storage stability</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4948789">US4948789</a></td><td class="patent-data-table-td patent-date-value">Mar 28, 1989</td><td class="patent-data-table-td patent-date-value">Aug 14, 1990</td><td class="patent-data-table-td ">Chugai Seiyaku Kabushiki Kaisha</td><td class="patent-data-table-td ">Suppression of parathyroid hormone synthesis and secretion</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5063221">US5063221</a></td><td class="patent-data-table-td patent-date-value">Mar 29, 1990</td><td class="patent-data-table-td patent-date-value">Nov 5, 1991</td><td class="patent-data-table-td ">Chugai Seiyaku Kabushiki Kaisha</td><td class="patent-data-table-td ">Treatment for hyperparathyroidism with use of vitamin d derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5085864">US5085864</a></td><td class="patent-data-table-td patent-date-value">May 20, 1991</td><td class="patent-data-table-td patent-date-value">Feb 4, 1992</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Injectable formulation for lipophilic drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5092840">US5092840</a></td><td class="patent-data-table-td patent-date-value">Jul 16, 1990</td><td class="patent-data-table-td patent-date-value">Mar 3, 1992</td><td class="patent-data-table-td ">Healy Patrick M</td><td class="patent-data-table-td ">Transfer of medication from container to patient</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5104864">US5104864</a></td><td class="patent-data-table-td patent-date-value">Aug 17, 1990</td><td class="patent-data-table-td patent-date-value">Apr 14, 1992</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Method for treating and preventing loss of bone mass</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5120720">US5120720</a></td><td class="patent-data-table-td patent-date-value">Sep 20, 1990</td><td class="patent-data-table-td patent-date-value">Jun 9, 1992</td><td class="patent-data-table-td ">The United States Of America As Represented By The Secretary Of The Department Of Health &amp; Human Services</td><td class="patent-data-table-td ">Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5124152">US5124152</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 7, 1991</td><td class="patent-data-table-td patent-date-value">Jun 23, 1992</td><td class="patent-data-table-td ">Fisons Corporation</td><td class="patent-data-table-td ">Parenteral formulation of metolazone</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5134127">US5134127</a></td><td class="patent-data-table-td patent-date-value">Jan 23, 1990</td><td class="patent-data-table-td patent-date-value">Jul 28, 1992</td><td class="patent-data-table-td ">University Of Kansas</td><td class="patent-data-table-td ">Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5141719">US5141719</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 1990</td><td class="patent-data-table-td patent-date-value">Aug 25, 1992</td><td class="patent-data-table-td ">Bio-Rad Laboratories, Inc.</td><td class="patent-data-table-td ">Multilayer of upper plate with aperatures, membrane sheet, one-piece drop guide plate and lower plate with wells; concurrent, purification</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5157135">US5157135</a></td><td class="patent-data-table-td patent-date-value">Mar 21, 1990</td><td class="patent-data-table-td patent-date-value">Oct 20, 1992</td><td class="patent-data-table-td ">Nisshin Flour Milling Co., Ltd.</td><td class="patent-data-table-td ">Treatment of bone disorders, renal diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5158944">US5158944</a></td><td class="patent-data-table-td patent-date-value">Feb 28, 1990</td><td class="patent-data-table-td patent-date-value">Oct 27, 1992</td><td class="patent-data-table-td ">Teijin Limited</td><td class="patent-data-table-td ">Dispersed in excipient readily soluble in organic solvent, and basic substance</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5182274">US5182274</a></td><td class="patent-data-table-td patent-date-value">Sep 21, 1989</td><td class="patent-data-table-td patent-date-value">Jan 26, 1993</td><td class="patent-data-table-td ">Teijin Limited</td><td class="patent-data-table-td ">Nonionic surfactant, citric acid or tartaric acid chelating agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5205989">US5205989</a></td><td class="patent-data-table-td patent-date-value">Sep 18, 1991</td><td class="patent-data-table-td patent-date-value">Apr 27, 1993</td><td class="patent-data-table-td ">Minnesota Mining And Manufacturing Company</td><td class="patent-data-table-td ">Pivotable member that secures multi-well filtration plate to housing</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5219528">US5219528</a></td><td class="patent-data-table-td patent-date-value">Aug 6, 1991</td><td class="patent-data-table-td patent-date-value">Jun 15, 1993</td><td class="patent-data-table-td ">Pierce Chemical Company</td><td class="patent-data-table-td ">Apparatus for rapid immunoassays</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5232836">US5232836</a></td><td class="patent-data-table-td patent-date-value">Feb 18, 1992</td><td class="patent-data-table-td patent-date-value">Aug 3, 1993</td><td class="patent-data-table-td ">Ire-Medgenix S.A.</td><td class="patent-data-table-td ">Vitamin D derivatives: therapeutic applications and applications to assays of metabolites of vitamin D</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5260290">US5260290</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 1991</td><td class="patent-data-table-td patent-date-value">Nov 9, 1993</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Homologated vitamin D2 compounds and the corresponding 1α-hydroxylated derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5264184">US5264184</a></td><td class="patent-data-table-td patent-date-value">Mar 19, 1991</td><td class="patent-data-table-td patent-date-value">Nov 23, 1993</td><td class="patent-data-table-td ">Minnesota Mining And Manufacturing Company</td><td class="patent-data-table-td ">Device and a method for separating liquid samples</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5264618">US5264618</a></td><td class="patent-data-table-td patent-date-value">Apr 16, 1991</td><td class="patent-data-table-td patent-date-value">Nov 23, 1993</td><td class="patent-data-table-td ">Vical, Inc.</td><td class="patent-data-table-td ">For transport of biological active agents into cells for viral agents or polynucleotides or immunogenic peptides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5298246">US5298246</a></td><td class="patent-data-table-td patent-date-value">Dec 31, 1991</td><td class="patent-data-table-td patent-date-value">Mar 29, 1994</td><td class="patent-data-table-td ">Kanegafuchi Kagaku Kogyo Kabushiki Kaisha</td><td class="patent-data-table-td ">Stable pharmaceutical composition and method for its production</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5334740">US5334740</a></td><td class="patent-data-table-td patent-date-value">Mar 13, 1992</td><td class="patent-data-table-td patent-date-value">Aug 2, 1994</td><td class="patent-data-table-td ">Kurary Co., Ltd.</td><td class="patent-data-table-td ">Cyclohexanetriol derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5338532">US5338532</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 1991</td><td class="patent-data-table-td patent-date-value">Aug 16, 1994</td><td class="patent-data-table-td ">The Dow Chemical Company</td><td class="patent-data-table-td ">Starburst conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5360413">US5360413</a></td><td class="patent-data-table-td patent-date-value">May 19, 1993</td><td class="patent-data-table-td patent-date-value">Nov 1, 1994</td><td class="patent-data-table-td ">Filtertek, Inc.</td><td class="patent-data-table-td ">Needleless access device</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5366965">US5366965</a></td><td class="patent-data-table-td patent-date-value">Jan 29, 1993</td><td class="patent-data-table-td patent-date-value">Nov 22, 1994</td><td class="patent-data-table-td ">Boehringer Mannheim Gmbh</td><td class="patent-data-table-td ">Regimen for treatment or prophylaxis of osteoporosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5372996">US5372996</a></td><td class="patent-data-table-td patent-date-value">Oct 19, 1992</td><td class="patent-data-table-td patent-date-value">Dec 13, 1994</td><td class="patent-data-table-td ">Endorecherche, Inc.</td><td class="patent-data-table-td ">Method of treatment of androgen-related diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5376645">US5376645</a></td><td class="patent-data-table-td patent-date-value">Jul 27, 1992</td><td class="patent-data-table-td patent-date-value">Dec 27, 1994</td><td class="patent-data-table-td ">University Of Kansas</td><td class="patent-data-table-td ">Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5403831">US5403831</a></td><td class="patent-data-table-td patent-date-value">Sep 10, 1993</td><td class="patent-data-table-td patent-date-value">Apr 4, 1995</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Method of treating and preventing loss of bone mass using 1α-hydroxy-vitamin D2</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5417923">US5417923</a></td><td class="patent-data-table-td patent-date-value">Jan 18, 1994</td><td class="patent-data-table-td patent-date-value">May 23, 1995</td><td class="patent-data-table-td ">Pfizer Inc.</td><td class="patent-data-table-td ">Plastics molded test tray mounted to collection tray; analysis; chromatography; no cross-contamination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5474923">US5474923</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1991</td><td class="patent-data-table-td patent-date-value">Dec 12, 1995</td><td class="patent-data-table-td ">Mercian Corporation</td><td class="patent-data-table-td ">Adding Vitamin D compound having hydrogen atom at position 25 and cyclodextrin compounds to reaction mixture containing microorganism or enzyme extract capable of hydroxylating Vitamin D, recovering product</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5487900">US5487900</a></td><td class="patent-data-table-td patent-date-value">Feb 7, 1994</td><td class="patent-data-table-td patent-date-value">Jan 30, 1996</td><td class="patent-data-table-td ">Takeda Chemical Industries, Limited</td><td class="patent-data-table-td ">Stabilized vitamin D preparation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5488120">US5488120</a></td><td class="patent-data-table-td patent-date-value">Aug 24, 1994</td><td class="patent-data-table-td patent-date-value">Jan 30, 1996</td><td class="patent-data-table-td ">Lunar Corporation</td><td class="patent-data-table-td ">1α-hydroxy vitamin D4 and novel intermediates and analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5527524">US5527524</a></td><td class="patent-data-table-td patent-date-value">Apr 5, 1993</td><td class="patent-data-table-td patent-date-value">Jun 18, 1996</td><td class="patent-data-table-td ">The Dow Chemical Company</td><td class="patent-data-table-td ">Dense star polymer conjugates</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5532229">US5532229</a></td><td class="patent-data-table-td patent-date-value">May 3, 1994</td><td class="patent-data-table-td patent-date-value">Jul 2, 1996</td><td class="patent-data-table-td ">Vieth; Reinhold W.</td><td class="patent-data-table-td ">Cream of vitamin d</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5549577">US5549577</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 1993</td><td class="patent-data-table-td patent-date-value">Aug 27, 1996</td><td class="patent-data-table-td ">Ivac Corporation</td><td class="patent-data-table-td ">Needleless connector</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5554386">US5554386</a></td><td class="patent-data-table-td patent-date-value">Jun 16, 1994</td><td class="patent-data-table-td patent-date-value">Sep 10, 1996</td><td class="patent-data-table-td ">Advanced Magnetics, Inc.</td><td class="patent-data-table-td ">Complexing; internalization into cells by receptor mediated endocytosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5561123">US5561123</a></td><td class="patent-data-table-td patent-date-value">May 16, 1995</td><td class="patent-data-table-td patent-date-value">Oct 1, 1996</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Antitumor agents, anticarcinogenic agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5565442">US5565442</a></td><td class="patent-data-table-td patent-date-value">Sep 13, 1993</td><td class="patent-data-table-td patent-date-value">Oct 15, 1996</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">Dissolving in solvent with antioxidant and polyoxyalkyl stabilizer; compositing with carrier or excipient to impart solid characteristics; desolventizing; useful in conditions of vitamin d deficiency</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5597575">US5597575</a></td><td class="patent-data-table-td patent-date-value">Jun 6, 1994</td><td class="patent-data-table-td patent-date-value">Jan 28, 1997</td><td class="patent-data-table-td ">Breitbarth; Richard</td><td class="patent-data-table-td ">Composition for stimulating and inducing hair growth</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5602116">US5602116</a></td><td class="patent-data-table-td patent-date-value">Apr 3, 1995</td><td class="patent-data-table-td patent-date-value">Feb 11, 1997</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Administering vitamin d analog</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5614513">US5614513</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Mar 25, 1997</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Release agent binder for vitamin d compounds and derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5632315">US5632315</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 1994</td><td class="patent-data-table-td patent-date-value">May 27, 1997</td><td class="patent-data-table-td ">Rose; Howard</td><td class="patent-data-table-td ">Liquid dispensers</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5637742">US5637742</a></td><td class="patent-data-table-td patent-date-value">Nov 1, 1994</td><td class="patent-data-table-td patent-date-value">Jun 10, 1997</td><td class="patent-data-table-td ">Duphar International Research B.V.</td><td class="patent-data-table-td ">Wound healing agents, skin disorders, cosmetics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5645856">US5645856</a></td><td class="patent-data-table-td patent-date-value">Mar 16, 1995</td><td class="patent-data-table-td patent-date-value">Jul 8, 1997</td><td class="patent-data-table-td ">R. P. Scherer Corporation</td><td class="patent-data-table-td ">Delivery systems for hydrophobic drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5661025">US5661025</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Aug 26, 1997</td><td class="patent-data-table-td ">Univ California</td><td class="patent-data-table-td ">Self-assembling polynucleotide delivery system comprising dendrimer polycations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5668174">US5668174</a></td><td class="patent-data-table-td patent-date-value">Oct 14, 1994</td><td class="patent-data-table-td patent-date-value">Sep 16, 1997</td><td class="patent-data-table-td ">Kowa Tekuno Sachi Co., Ltd.</td><td class="patent-data-table-td ">Gamma-linolenic acid or dihomo-g-linolenic acid</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5691328">US5691328</a></td><td class="patent-data-table-td patent-date-value">Aug 27, 1996</td><td class="patent-data-table-td patent-date-value">Nov 25, 1997</td><td class="patent-data-table-td ">Clarion Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Antitumor agents; antiinflammatory agents; skin disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5716346">US5716346</a></td><td class="patent-data-table-td patent-date-value">Jul 2, 1993</td><td class="patent-data-table-td patent-date-value">Feb 10, 1998</td><td class="patent-data-table-td ">Farris; Barry</td><td class="patent-data-table-td ">Method and apparatus for loading syringes without the need for hypodermic needles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5739271">US5739271</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Apr 14, 1998</td><td class="patent-data-table-td ">Gen-Probe Incorporated</td><td class="patent-data-table-td ">Drug delivery of oligonucleotides, nucleic acids, peptides, images, and proteins</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5763428">US5763428</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Jun 9, 1998</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Administering active nontoxic derivatives for skin or metabolic disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5763429">US5763429</a></td><td class="patent-data-table-td patent-date-value">Dec 30, 1996</td><td class="patent-data-table-td patent-date-value">Jun 9, 1998</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Method of treating prostatic diseases using active vitamin D analogues</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5766582">US5766582</a></td><td class="patent-data-table-td patent-date-value">Oct 11, 1994</td><td class="patent-data-table-td patent-date-value">Jun 16, 1998</td><td class="patent-data-table-td ">Schering Corporation</td><td class="patent-data-table-td ">Storage stability; mixture with buffer, stabilizer and chelate compound</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5795882">US5795882</a></td><td class="patent-data-table-td patent-date-value">Dec 30, 1996</td><td class="patent-data-table-td patent-date-value">Aug 18, 1998</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5798345">US5798345</a></td><td class="patent-data-table-td patent-date-value">Jun 7, 1995</td><td class="patent-data-table-td patent-date-value">Aug 25, 1998</td><td class="patent-data-table-td ">Bone Care International, Inc.</td><td class="patent-data-table-td ">Method of inhibiting the hyperproliferation of malignant cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5804573">US5804573</a></td><td class="patent-data-table-td patent-date-value">May 31, 1996</td><td class="patent-data-table-td patent-date-value">Sep 8, 1998</td><td class="patent-data-table-td ">Teva Pharmaceutical Industries Ltd.</td><td class="patent-data-table-td ">With additive antioxidant, polyoxyalkyl stabilizer, carrier</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5817648">US5817648</a></td><td class="patent-data-table-td patent-date-value">May 8, 1996</td><td class="patent-data-table-td patent-date-value">Oct 6, 1998</td><td class="patent-data-table-td ">Duphar International Research B.V.</td><td class="patent-data-table-td ">Vitamin D3 analogues having an unsaturated side chain</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5827883">US5827883</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jan 17, 1996</td><td class="patent-data-table-td patent-date-value">Oct 27, 1998</td><td class="patent-data-table-td ">Hoffmann-La Roche Inc.</td><td class="patent-data-table-td ">Topical drug delivery; side effect reduction</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5858999">US5858999</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 1995</td><td class="patent-data-table-td patent-date-value">Jan 12, 1999</td><td class="patent-data-table-td ">Pharmacia &amp; Upjohn Company</td><td class="patent-data-table-td ">Cosolvent parenteral formulation of tirilazad</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5869386">US5869386</a></td><td class="patent-data-table-td patent-date-value">Sep 23, 1996</td><td class="patent-data-table-td patent-date-value">Feb 9, 1999</td><td class="patent-data-table-td ">Nec Corporation</td><td class="patent-data-table-td ">Method of fabricating a composite silicon-on-insulator substrate</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5874418">US5874418</a></td><td class="patent-data-table-td patent-date-value">May 5, 1997</td><td class="patent-data-table-td patent-date-value">Feb 23, 1999</td><td class="patent-data-table-td ">Cydex, Inc.</td><td class="patent-data-table-td ">Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5880114">US5880114</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 1996</td><td class="patent-data-table-td patent-date-value">Mar 9, 1999</td><td class="patent-data-table-td ">Wisconsin Alumni Research Foundation</td><td class="patent-data-table-td ">Treatment of immune deficiency with vitamin D compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5932544">US5932544</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 31, 1994</td><td class="patent-data-table-td patent-date-value">Aug 3, 1999</td><td class="patent-data-table-td ">Xoma Corporation</td><td class="patent-data-table-td ">Mixture with lipid carrier</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5939407">US5939407</a></td><td class="patent-data-table-td patent-date-value">Oct 1, 1997</td><td class="patent-data-table-td patent-date-value">Aug 17, 1999</td><td class="patent-data-table-td ">University Of Kentucky Research Foundation</td><td class="patent-data-table-td ">Vitamin d receptors for nervous system disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5965160">US5965160</a></td><td class="patent-data-table-td patent-date-value">Apr 24, 1995</td><td class="patent-data-table-td patent-date-value">Oct 12, 1999</td><td class="patent-data-table-td ">Yissum Research Development Company Of The Hebrew University Of Jerusalem</td><td class="patent-data-table-td ">Self-emulsifiable formulation producing an oil-in-water emulsion</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5972917">US5972917</a></td><td class="patent-data-table-td patent-date-value">May 29, 1998</td><td class="patent-data-table-td patent-date-value">Oct 26, 1999</td><td class="patent-data-table-td ">Bone Care Int Inc</td><td class="patent-data-table-td ">Treatment and prophylaxis of hyperparathyroidism and hyperproliferative diseases, and in the modulation of the immune and inflammatory responses as well as the treatment of bone depletive disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6045538">US6045538</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 1997</td><td class="patent-data-table-td patent-date-value">Apr 4, 2000</td><td class="patent-data-table-td ">Farris; Barry</td><td class="patent-data-table-td ">Method and apparatus for loading syringes without the need for hypodermic needles</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6046177">US6046177</a></td><td class="patent-data-table-td patent-date-value">Jan 13, 1999</td><td class="patent-data-table-td patent-date-value">Apr 4, 2000</td><td class="patent-data-table-td ">Cydex, Inc.</td><td class="patent-data-table-td ">Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6051567">US6051567</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 1999</td><td class="patent-data-table-td patent-date-value">Apr 18, 2000</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Stable aqueous solution</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6096338">US6096338</a></td><td class="patent-data-table-td patent-date-value">Jun 27, 1997</td><td class="patent-data-table-td patent-date-value">Aug 1, 2000</td><td class="patent-data-table-td ">R. P. Scherer Corporation</td><td class="patent-data-table-td ">Delivery systems for hydrophobic drugs</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6136799">US6136799</a></td><td class="patent-data-table-td patent-date-value">Apr 8, 1998</td><td class="patent-data-table-td patent-date-value">Oct 24, 2000</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Cosolvent formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6171603">US6171603</a></td><td class="patent-data-table-td patent-date-value">Feb 9, 1999</td><td class="patent-data-table-td patent-date-value">Jan 9, 2001</td><td class="patent-data-table-td ">Centre International De Recherches Dermatologiques Galderma</td><td class="patent-data-table-td ">Treating skin, hair, cardiovascular, autoimmune and vision disorders; administering as anticarcinogenic, antidepressant,antiinflammatory, and antiacne agents</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6211169">US6211169</a></td><td class="patent-data-table-td patent-date-value">Sep 29, 1999</td><td class="patent-data-table-td patent-date-value">Apr 3, 2001</td><td class="patent-data-table-td ">Aesgen, Inc.</td><td class="patent-data-table-td ">Stable calcitriol solution for packaging into vials</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Abood et al., "<a href='http://scholar.google.com/scholar?q="Pharmacy+Practice+and+the+Law%2C"'>Pharmacy Practice and the Law,</a>" (1994) pp. 27-28.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Aloia, J. et al., Amer. J. Med., (1988) 84:401-08.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Barton, D. et al., "<a href='http://scholar.google.com/scholar?q="Synthetic+Uses+of+Steroidal+Ring+%26amp%3B+Diene+Protection%3A+22%2C23-Dihydroergosterol%2C"'>Synthetic Uses of Steroidal Ring &amp; Diene Protection: 22,23-Dihydroergosterol,</a>" JCS Perkin I, (1976) pp. 821-826.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Beer, et al., "<a href='http://scholar.google.com/scholar?q="A+Phase+I+Trial+of+Pulse+Calcitriol+in+Patients+with+Refractory+Malignancies%2C"'>A Phase I Trial of Pulse Calcitriol in Patients with Refractory Malignancies,</a>" Cancer, (Jun. 15, 2001) 91:12:2431-2439.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Beer, et al., "<a href='http://scholar.google.com/scholar?q="Weekly+High-Dose+Calcitriol+and+Docetaxel+in+Advanced+Prostate+Cancer%2C"'>Weekly High-Dose Calcitriol and Docetaxel in Advanced Prostate Cancer,</a>" Seminars in Oncology, Suppl 15 (Aug. 2001) 28:4:49-55.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Beer, T. et al., "<a href='http://scholar.google.com/scholar?q="Weekly+High-Dose+Calcitriol+and+Docetaxel+in+Metastatic+Androgen-Independent+Prostate+Cancer%2C"'>Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer,</a>" Journal of Clinical Oncology, (Jan. 2003) 21:1:123-128.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Blazsek, I. et al. "<a href='http://scholar.google.com/scholar?q="Combined+Differentiation+Therapy+in+Myelodysplastic+Syndrome+with+Retinoid+Acid%2C+1alpha%2C25+Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%2C+and+Prednisone%2C"'>Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1alpha,25 Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;, and Prednisone,</a>" 16:4:259-264 (Abstract).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Braunwald, E. et al., Harrison's Principles of Internal Medicine: Part Eleven, "<a href='http://scholar.google.com/scholar?q="Disorders+of+Bone+and+Mineral+Metabolism%2C"'>Disorders of Bone and Mineral Metabolism,</a>" Chapter 335, McGraw-Hill, New York, (1987) pp. 1860-1865.</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brautbar, N. "<a href='http://scholar.google.com/scholar?q="Osteoporosis%3A+Is+1%2C25-%28OH%292D3+of+Value+in+Treatment%3F"'>Osteoporosis: Is 1,25-(OH)2D3 of Value in Treatment?</a>" Nephron (1986) 44:161-166.</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Brown, J.P. et al., "<a href='http://scholar.google.com/scholar?q="Serum+Bone+Gala-Protein%3A+A+Specific+Marker+for+Bone+Formation+in+Postmenopausal+Osteoporosis%2C"'>Serum Bone Gala-Protein: A Specific Marker for Bone Formation in Postmenopausal Osteoporosis,</a>" Lancet, (1984) 1:1091-1093.</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Caniggia, A. et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+a+Long-Term+Treatment+with+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bon+Osteocalcin+in+Postmenopausal+Osteoporosis%2C"'>Effect of a Long-Term Treatment with 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;on Osteocalcin in Postmenopausal Osteoporosis,</a>" Cacified Tissue Int., (1986) 38:328-332.</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Cho, Y.L. et al., "<a href='http://scholar.google.com/scholar?q="Combined+Effects+of+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+Platinum+Drugs+on+the+growth+of+MCF-7+Cells%2C"'>Combined Effects of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Platinum Drugs on the growth of MCF-7 Cells,</a>" Cancer Research, (Jun. 1991) 51:2848-2853.</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Christiansen, C. et al., "<a href='http://scholar.google.com/scholar?q="Prevention+of+Early+Postmenopausal+Bone+Loss%3A+Controlled+2-Year+Study+in+315+Normal+Females%2C"'>Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females,</a>" Europ J Clin Inves., (1980) 10:273-279.</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Christiansen, C. et al., Eur. J. Clin. Invest., (1981) 11:305-309.</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Crump, D.R. et al., "<a href='http://scholar.google.com/scholar?q="%2822S%29-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B4%26lt%3B%2FSUB%26gt%3B%2C"'>(22S)-Hydroxyvitamin D&lt;SUB&gt;4&lt;/SUB&gt;,</a>" J.C.S. Perkins Trans. I, (1973) pp. 2731-2733.</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Defacque, H. et al., "<a href='http://scholar.google.com/scholar?q="Different+Combinations+of+Retinoids+and+Vitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BAnalogs+Efficiently+Promote+Growth+Inhibition+and+Differentiation+of+Myelomonocytic+Leukemia+Cell+Lines%2C"'>Different Combinations of Retinoids and Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines,</a>" J. Pharmacology and Experimental Therapeutics, (1994) 271:193-199.</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">DeLuca et al., "<a href='http://scholar.google.com/scholar?q="Synthesis%2C+Biological+Activity%2C+and+Metabolism+of+22%2C23-%26lt%3BSUP%26gt%3B3%26lt%3B%2FSUP%26gt%3BH-Vitamin+D%26lt%3BSUB%26gt%3B4%26lt%3B%2FSUB%26gt%3B%2C"'>Synthesis, Biological Activity, and Metabolism of 22,23-&lt;SUP&gt;3&lt;/SUP&gt;H-Vitamin D&lt;SUB&gt;4&lt;/SUB&gt;,</a>" Arch. Biochem, Biophys., (1968) 124:122-128.</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Duda et al., "<a href='http://scholar.google.com/scholar?q="1%2C25-Dihydroxyvitamin+D+Stimulation+Test+for+Osteoblast+Function+in+Normal+and+Osteoporotic+Postmenopausal+Women%2C"'>1,25-Dihydroxyvitamin D Stimulation Test for Osteoblast Function in Normal and Osteoporotic Postmenopausal Women,</a>" J. Clinic Inves., (1987) 79:1249-1253.</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Endo, K. et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+Combination+Treatment+with+Vitamin+D+Analog+%28OCT%29+and+a+Biophosphonate+%28AHPrBP%29+in+a+Nude+Mouse+Model+of+Cancer-Associated+Hypercalcemia%2C"'>Effect of Combination Treatment with Vitamin D Analog (OCT) and a Biophosphonate (AHPrBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia,</a>" Journal of Bone and Mineral Research, (1998) 13:9:1378-1383.</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Foldes, J. et al., "<a href='http://scholar.google.com/scholar?q="Long+Term+Treatment+with+1alpha+%28OH%29D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bfor+Postmenopausal+Osteoporosis%3A+Efficacy+and+Safety%2C"'>Long Term Treatment with 1alpha (OH)D&lt;SUB&gt;3 &lt;/SUB&gt;for Postmenopausal Osteoporosis: Efficacy and Safety,</a>" Osteoporosis, (1987) 2:971-973.</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gallagher, J.C. et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+Increasing+Doses+of+1alpha-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Bon+Calcium+Homeostasis+in+Postmenopausal+Osteopenic+Women%2C"'>Effects of Increasing Doses of 1alpha-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;on Calcium Homeostasis in Postmenopausal Osteopenic Women,</a>" J. Bone Min. Res., (1994) 9:607-614.</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Gallagher, J.C., et al., Annals of Int. Med., (1990) 13:649-655.</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Grab, W. Z. Physiol. Chem., (1936) 243:63-89.</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, (1979) pp. 5-6.</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hershberger, P. et al. "<a href='http://scholar.google.com/scholar?q="Calcitriol+%281%2C25-Dihydroxycholecalciferol%29+Enhances+Paclitaxel+Antitumor+Activity+in+Vitro+and+in+Vivo+and+Accelerates+Paclitaxel-induced+Apoptosis%2C"'>Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity in Vitro and in Vivo and Accelerates Paclitaxel-induced Apoptosis,</a>" Clinical Cancer Research, (Apr. 2001) 7:1043-1051.</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hoikka, V. et al., "<a href='http://scholar.google.com/scholar?q="Treatment+of+Osteoporosis+with+1-Alpha-Hydroxycholecalciferol+and+Calcium%2C"'>Treatment of Osteoporosis with 1-Alpha-Hydroxycholecalciferol and Calcium,</a>" Acta. Med. Scand.(1980) 207:221-224.</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Holick, M.F. et al., Proc. Natl. Acad. Sci. USA, (1971) 68:803-804.</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Holick, M.F. et al., Science (1973) pp. 180, 190-191.</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Holick, M.F., "<a href='http://scholar.google.com/scholar?q="Noncalcemic+Actions+of+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+Clinical+Applications"'>Noncalcemic Actions of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Clinical Applications</a>", Bone, (1995) 17:2:107S-110S.</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Horst et al., "<a href='http://scholar.google.com/scholar?q="Discrimination+in+the+Metabolism+of+Orally+Dosed+Ergocalciferol+and+Cholecalciferol+by+the+Pig%2C+Rat+and+Chick%2C"'>Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick,</a>" Biochem. J., (1982) 204:185-189.</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Horst et al., "<a href='http://scholar.google.com/scholar?q="Quantitation+of+Vitamin+D+and+its+Metabolites+and+Their+Plasma+Concentrations+in+Five+Species+of+Animals%2C"'>Quantitation of Vitamin D and its Metabolites and Their Plasma Concentrations in Five Species of Animals,</a>" Anal. Biochem., (1981) 116:189-203.</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Jensen, G.F. et al., Clin. Endocrinol., (1982) 16:515-524.</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Johnson, C. et al. "<a href='http://scholar.google.com/scholar?q="Vitamin+D-related+Therapies+in+Prostate+Cancer%2C"'>Vitamin D-related Therapies in Prostate Cancer,</a>" Cancer and Metastasis Review 21, (2002) pp. 147-158.</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kanis, J.A. et al., "<a href='http://scholar.google.com/scholar?q="Guidelines+for+Clinical+Trials+in+Osteoporosis%2C+A+Position+Paper+of+the+European+Foundation+for+Osteoporosis%2C"'>Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis,</a>" Osteoporosis Int., (1991) 1:182-188.</td></tr><tr><td class="patent-data-table-td ">35</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kim, S. et al., Potentiation of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;-Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone, Biochem. Pharmacology, (2002) 64:1233-1242.</td></tr><tr><td class="patent-data-table-td ">36</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Knutson, et al., "<a href='http://scholar.google.com/scholar?q="Metabolism+of+1+alpha-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Bto+activated+Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3BMetabolites+Decreases+Endogenous+1alpha%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bin+Rats+and+Monkeys%2C"'>Metabolism of 1 alpha-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;to activated Dihydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;Metabolites Decreases Endogenous 1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;in Rats and Monkeys,</a>" Endocrinology, (1995) 136:11:4749-4753.</td></tr><tr><td class="patent-data-table-td ">37</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kocienski, P.J. et al., "<a href='http://scholar.google.com/scholar?q="Calciferol+and+its+Relatives.+A+Synthesis+of+Vitamin+D%26lt%3BSUB%26gt%3B4%26lt%3B%2FSUB%26gt%3B%2C"'>Calciferol and its Relatives. A Synthesis of Vitamin D&lt;SUB&gt;4&lt;/SUB&gt;,</a>" J.C.S. Perkins I, (1979) pp. 1290-1293.</td></tr><tr><td class="patent-data-table-td ">38</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Lam, H.Y. et al., Science , (1974) 486:1038-1040.</td></tr><tr><td class="patent-data-table-td ">39</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Londowski, J.M. et al., "<a href='http://scholar.google.com/scholar?q="Biological+Activity+of+the+C-1%2C+C-3%2C+C-25%2C+beta-D-Glucopyranosides+of+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%26lt%3BSUP%26gt%3B1%26lt%3B%2FSUP%26gt%3B%2C"'>Biological Activity of the C-1, C-3, C-25, beta-D-Glucopyranosides of 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;&lt;SUP&gt;1&lt;/SUP&gt;,</a>" J. Pharmacology Expr. Ther., (1986) 237:3:837-840.</td></tr><tr><td class="patent-data-table-td ">40</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Majewski, et al., "<a href='http://scholar.google.com/scholar?q="Inhibition+of+Tumor+Cell-Induced+Angiogenisis+by+Retinoids%2C+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+their+Combination%2C"'>Inhibition of Tumor Cell-Induced Angiogenisis by Retinoids, 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and their Combination,</a>" Cancer Letters, (1993) 75:35-39.</td></tr><tr><td class="patent-data-table-td ">41</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Martin and DeLuca, "<a href='http://scholar.google.com/scholar?q="Calcium+Transport%2C"'>Calcium Transport,</a>" Am. J. Physiol., 216:1352-1359.</td></tr><tr><td class="patent-data-table-td ">42</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Mathias, C.J. et al., "<a href='http://scholar.google.com/scholar?q="Tumor-Selective+Radiopharmaceutical+Targeting+Via+Receptor-Mediated+Endocytosis+of+Gallium-67-Deferoxamine-Folate%2C"'>Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate,</a>" J. Nucl. Med. (1996), 37(6):1003-1008.</td></tr><tr><td class="patent-data-table-td ">43</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">McDonald, F.G., "<a href='http://scholar.google.com/scholar?q="The+Multiple+Nature+of+Vitamin+D%2C"'>The Multiple Nature of Vitamin D,</a>" J. Biol. Chem. 114, (1936) 1xv.</td></tr><tr><td class="patent-data-table-td ">44</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Merck Index, S. Budavari (ed.), 11th ed., Merck &amp; Co., Rahway, N.J. (1989) pp. 1579, #9930.</td></tr><tr><td class="patent-data-table-td ">45</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Miller et al., "<a href='http://scholar.google.com/scholar?q="The+Human+Prostatic+Carcinoma+Cell+Line+LNCaP+Expresses+Biologically+Active%2C+Specific+Receptors+for+1alpha%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%26lt%3BSUP%26gt%3B1%26lt%3B%2FSUP%26gt%3B%2C"'>The Human Prostatic Carcinoma Cell Line LNCaP Expresses Biologically Active, Specific Receptors for 1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;&lt;SUP&gt;1&lt;/SUP&gt;,</a>" Cancer Res., (1992) 52:515-520.</td></tr><tr><td class="patent-data-table-td ">46</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Moffatt, K. et al., "<a href='http://scholar.google.com/scholar?q="1alpha%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+Platinum+Drugs+Act+Synergistically+to+Inhibit+the+Growth+of+Prostate+Cancer+Cell+Lines%2C"'>1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines,</a>" Clinical Cancer Research, (Mar. 1999) 5:695-703.</td></tr><tr><td class="patent-data-table-td ">47</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Muindi, J. et al., "<a href='http://scholar.google.com/scholar?q="Pharmacokinetics+of+High-Dose+Oral+Calcitriol%3A+Results+From+a+Phase+1+Trial+of+Calcitriol+and+Paclitaxel%2C"'>Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase 1 Trial of Calcitriol and Paclitaxel,</a>" Clinical Pharmacology &amp; Therapeutics, (Dec. 2002) pp. 648-659.</td></tr><tr><td class="patent-data-table-td ">48</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Nemeto, H. et al., "<a href='http://scholar.google.com/scholar?q="A+Stereoselective+Synthesis+of+1+alpha-Hydroxy-Vitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%2C"'>A Stereoselective Synthesis of 1 alpha-Hydroxy-Vitamin D&lt;SUB&gt;3&lt;/SUB&gt;,</a>" Chemistry Letters, (1985) 8:1131-1132.</td></tr><tr><td class="patent-data-table-td ">49</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Orimo, H. et al., "<a href='http://scholar.google.com/scholar?q="Reduced+Occurrence+of+Vertebral+Crush+Fractures+in+Senile+Osteoporosis+Treated+with+1alpha%28OH%29-Vitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%2C"'>Reduced Occurrence of Vertebral Crush Fractures in Senile Osteoporosis Treated with 1alpha(OH)-Vitamin D&lt;SUB&gt;3&lt;/SUB&gt;,</a>" Bone and Mineral, (1987) 3:47-52.</td></tr><tr><td class="patent-data-table-td ">50</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ott, S.M. and C.H. Chestnut, Annals of Int. Med., (1989) 110:267-274.</td></tr><tr><td class="patent-data-table-td ">51</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Paaren et al., "<a href='http://scholar.google.com/scholar?q="Direct+C%281%29+Hydroxylation+of+Vitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+Related+Compounds%2C"'>Direct C(1) Hydroxylation of Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and Related Compounds,</a>" J. Org. Chem., (1980) 45:3253.</td></tr><tr><td class="patent-data-table-td ">52</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Packman, K. et al. "<a href='http://scholar.google.com/scholar?q="Combination+Treatment+of+MCF-7+Xenografts+with+the+Vitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BAnalog+EB1089+and+Antiestrogens%2C"'>Combination Treatment of MCF-7 Xenografts with the Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Analog EB1089 and Antiestrogens,</a>" (Vitamin D Endocrine Workshop, Nashville, TN May 27-Jun. 1, 2000) pp. 511-514.</td></tr><tr><td class="patent-data-table-td ">53</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Parfitt, "<a href='http://scholar.google.com/scholar?q="Martindale%2C+The+Complete+Drug+Reference%2C"'>Martindale, The Complete Drug Reference,</a>" (1999) pp. 1366-1369.</td></tr><tr><td class="patent-data-table-td ">54</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Physicians's Desk Reference, Edition 43:1746-1748.</td></tr><tr><td class="patent-data-table-td ">55</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Podenphant, J. et al., "<a href='http://scholar.google.com/scholar?q="Serum+Bone+Gla+Protein+and+Other+Biochemical+Estimates+of+Bone+Turnover+in+Early+Postmenopausal+Women+During+Prophylactic+Treatment+for+Osteoporosis%2C"'>Serum Bone Gla Protein and Other Biochemical Estimates of Bone Turnover in Early Postmenopausal Women During Prophylactic Treatment for Osteoporosis,</a>" Acta Med Scand, (1985) 218:329-333.</td></tr><tr><td class="patent-data-table-td ">56</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pouilles, J.M. et al., "<a href='http://scholar.google.com/scholar?q="Prevention+of+Early+Postmenopausal+Bone+Loss+with+1alpha-Hydroxy+Vitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%2C+A+Three-Year+Prospective+Study%2C"'>Prevention of Early Postmenopausal Bone Loss with 1alpha-Hydroxy Vitamin D&lt;SUB&gt;3&lt;/SUB&gt;, A Three-Year Prospective Study,</a>" Clin Rheumatol. 11, 4 (1992) pp. 492-497.</td></tr><tr><td class="patent-data-table-td ">57</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ravid, A. et al., "<a href='http://scholar.google.com/scholar?q="1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BEnhances+the+Susceptibility+of+Brease+Cancer+Cells+to+Doxorubicin-induced+Oxidative+Damage%2C"'>1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Enhances the Susceptibility of Brease Cancer Cells to Doxorubicin-induced Oxidative Damage,</a>" Cancer Research, (Feb. 15, 1999) 59:862-867.</td></tr><tr><td class="patent-data-table-td ">58</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Reeve, L.E. et al., "<a href='http://scholar.google.com/scholar?q="Biological+Activity+of+1alpha-hydroxy+Vitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Bin+the+Rat%2C"'>Biological Activity of 1alpha-hydroxy Vitamin D&lt;SUB&gt;2 &lt;/SUB&gt;in the Rat,</a>" Arch. Biochem. Biophys. (Feb. 1978) 186:1:164-167.</td></tr><tr><td class="patent-data-table-td ">59</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sato, F. et al., "<a href='http://scholar.google.com/scholar?q="Biological+Activity+of+1alpha%2C25-Dihydroxyvitamin+D+Derivatives-24-epi-1alpha%2C25-Dihydroxyvitamin+D-2+and+1alpha%2C25-Dihydroxyvitamin+D-7%2C"'>Biological Activity of 1alpha,25-Dihydroxyvitamin D Derivatives-24-epi-1alpha,25-Dihydroxyvitamin D-2 and 1alpha,25-Dihydroxyvitamin D-7,</a>" Biochim. Biophys. Acta, (1991) 1091:188-192.</td></tr><tr><td class="patent-data-table-td ">60</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Shiraki, M. et al., Endocrinol. Japan, (1985) 32:305-315.</td></tr><tr><td class="patent-data-table-td ">61</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Siwinska, A. et al. "<a href='http://scholar.google.com/scholar?q="Potentiation+of+the+Antiproliferative+Effect+in+Vitro+of+Doxorubicin%2C+Cisplatin+and+Genistein+by+New+Analogues+of+Vitamin+D%2C"'>Potentiation of the Antiproliferative Effect in Vitro of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D,</a>" Anticancer Research, (2001) 21:1925-1929.</td></tr><tr><td class="patent-data-table-td ">62</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sjoden et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+1+OHD%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Bon+Bone+Tissue%2C"'>Effects of 1 OHD&lt;SUB&gt;2 &lt;/SUB&gt;on Bone Tissue,</a>" Acta. Endocrinol. (Copenh.) (Aug. 1984) 16:4:564-568.</td></tr><tr><td class="patent-data-table-td ">63</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sjoden, G. et al., "<a href='http://scholar.google.com/scholar?q="1alpha-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Bis+Less+Toxic+than+1alpha-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bin+the+Rat%2C"'>1alpha-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;is Less Toxic than 1alpha-Hydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;in the Rat,</a>" Proc. Soc. Exp. Biol. Med., (1985) 178:432-436.</td></tr><tr><td class="patent-data-table-td ">64</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sjoden, G. et al., "<a href='http://scholar.google.com/scholar?q="Antirachitic+Activity+of+1alpha-Hydroxyergocalciferol+and+1alpha-Hydroxycholecalciferol+in+Rats%2C"'>Antirachitic Activity of 1alpha-Hydroxyergocalciferol and 1alpha-Hydroxycholecalciferol in Rats,</a>" J. Nutr., (1984) 114:2043-2046.</td></tr><tr><td class="patent-data-table-td ">65</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Skowronski et al., "<a href='http://scholar.google.com/scholar?q="Actions+Of+Vitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BAnalogs+on+Human+Prostate+Cancer+Cell+Lines%3A+Comparison+with+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%2C"'>Actions Of Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Analogs on Human Prostate Cancer Cell Lines: Comparison with 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;,</a>" Endocrinology, (1995) 136:20-26.</td></tr><tr><td class="patent-data-table-td ">66</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Skowronski et al., "<a href='http://scholar.google.com/scholar?q="Vitamin+D+and+Prostate+Cancer%3A+1%2C25+Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BReceptors+and+Actions+in+Human+Prostate+Cancer+Cell+Lines%2C"'>Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Receptors and Actions in Human Prostate Cancer Cell Lines,</a>" Endocrinology, (1993) 132:1952-1960.</td></tr><tr><td class="patent-data-table-td ">67</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Slapak, C. et al., "<a href='http://scholar.google.com/scholar?q="Treatment+of+Acute+Myeloid+Leukemia+in+the+Elderly+with+Low-Dose+Cytarabine%2C+Hydroxyurea%2C+and+Calcitriol%2C"'>Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol,</a>" Amer. J. Hematology, (1992) 41:178-183.</td></tr><tr><td class="patent-data-table-td ">68</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sommerfeldt et al., "<a href='http://scholar.google.com/scholar?q="Metabolism+of+Orally+Administered+%5B%26lt%3BSUP%26gt%3B3%26lt%3B%2FSUP%26gt%3BH%5DErgocalciferol+and+%5B%26lt%3BSUP%26gt%3B3%26lt%3B%2FSUP%26gt%3BH%5DCholecalciferol+by+Dairy+Calves%2C"'>Metabolism of Orally Administered [&lt;SUP&gt;3&lt;/SUP&gt;H]Ergocalciferol and [&lt;SUP&gt;3&lt;/SUP&gt;H]Cholecalciferol by Dairy Calves,</a>" J. Nutr., (1983) 11:2595-2600.</td></tr><tr><td class="patent-data-table-td ">69</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Song, X.D. et al., "<a href='http://scholar.google.com/scholar?q="Bryostatin-1+and+1alpha%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BSynergistically+Stimulated+the+Differentiation+of+NB4+Acute+Promyelocytic+Leukemia+Cells%2C"'>Bryostatin-1 and 1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Synergistically Stimulated the Differentiation of NB4 Acute Promyelocytic Leukemia Cells,</a>" Leukemia, (1999) 13:275-281.</td></tr><tr><td class="patent-data-table-td ">70</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sorensen, O.H. et al., Clin. Endocrinol., (1977) 7:169S-175S.</td></tr><tr><td class="patent-data-table-td ">71</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Strugnell et al., "<a href='http://scholar.google.com/scholar?q="1+alpha%2C24%28S%29-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B2%26lt%3B%2FSUB%26gt%3B%3A+a+biologically+active+product+of+1+alpha-hydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Bmade+in+the+human+hepatoma%2C+Hep3B%2C"'>1 alpha,24(S)-Dihydroxyvitamin D&lt;SUB&gt;2&lt;/SUB&gt;: a biologically active product of 1 alpha-hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;made in the human hepatoma, Hep3B,</a>" Biochem. J., (1995) 310-233-241.</td></tr><tr><td class="patent-data-table-td ">72</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Strugnell et al., "<a href='http://scholar.google.com/scholar?q="Metabolism+of+a+Cyclopropane-Ring-Containing+Analog+of+1alpha-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bin+a+Hepatocyte+Cell+Model%2C"'>Metabolism of a Cyclopropane-Ring-Containing Analog of 1alpha-Hydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;in a Hepatocyte Cell Model,</a>" Biochem. Pharm., (1990) 40:333-341.</td></tr><tr><td class="patent-data-table-td ">73</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Studzinski, G. et al., "<a href='http://scholar.google.com/scholar?q="Potentiation+by+1-alpha%2C25-+Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bof+Cytotoxicity+to+HL-60+Cells+Produced+by+Cytarabine+and+Hydroxyurea%2C"'>Potentiation by 1-alpha,25- Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea,</a>" J. National Cancer Inst., (Apr. 1986) 76:4:641-648.</td></tr><tr><td class="patent-data-table-td ">74</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Suzuki, Y. et al., "<a href='http://scholar.google.com/scholar?q="The+Enhancement+of+the+Chemotherapeutic+Effects+on+Human+Prostate+Cancer+Cell-The+Combination+with+the+Growth+Factor+Interaction+Inhibitor+%28Suramin%29%2C"'>The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell-The Combination with the Growth Factor Interaction Inhibitor (Suramin),</a>" Acta Urologica (1993) 12:1215-1220, (Abstract).</td></tr><tr><td class="patent-data-table-td ">75</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Swami, S. et al. "<a href='http://scholar.google.com/scholar?q="1alpha%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BDown-Regulates+Estrogen+Receptor+Abundance+and+Suppresses+Estrogen+Actions+in+MCF-7+Human+Breast+Cancer+Cells%2C"'>1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells,</a>" Clinical Cancer Research, (Aug. 2000) 6:3371-3379.</td></tr><tr><td class="patent-data-table-td ">76</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tachibana, Y. (Nisshin Flour Milling Co.), "<a href='http://scholar.google.com/scholar?q="Preparation+of+1Beta-Hydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Band+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B%2C"'>Preparation of 1Beta-Hydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;and D&lt;SUB&gt;3&lt;/SUB&gt;,</a>" Chemical Abstracts, (1990) 113:1:6688 Col. 2 Abstract No. 6683y.</td></tr><tr><td class="patent-data-table-td ">77</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tanaka, Y. et al., Endocrinology (1973) 92:417-422.</td></tr><tr><td class="patent-data-table-td ">78</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Torres, R. et al., Etoposide Stimulates 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells, Molecular and Cellular Biochemistry, (2000) 208:157-162.</td></tr><tr><td class="patent-data-table-td ">79</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Tsuji, M. et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+of+22%2C23-Dihydro-1alpha%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3Band+its+24R-Epimer%2C+New+Vitamin+D%26lt%3BSUB%26gt%3B2+%26lt%3B%2FSUB%26gt%3BDerivatives%2C"'>Synthesis of 22,23-Dihydro-1alpha,25-Dihydroxyvitamin D&lt;SUB&gt;2 &lt;/SUB&gt;and its 24R-Epimer, New Vitamin D&lt;SUB&gt;2 &lt;/SUB&gt;Derivatives,</a>" Bull. Chem. Soc. Jpn., (1990) 63:8:2233-2238.</td></tr><tr><td class="patent-data-table-td ">80</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wang, Q. et al., "<a href='http://scholar.google.com/scholar?q="1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+All-trans-Retinoic+Acid+Sensitize+Breast+Cancer+Cells+to+Chemotherapy-induced+Cell+Death%2C"'>1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and All-trans-Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death,</a>" Cancer Research, (Apr. 2000) 60:2040-2048.</td></tr><tr><td class="patent-data-table-td ">81</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wang, X. et al., "<a href='http://scholar.google.com/scholar?q="Inhibition+of+p38+MAP+Kinase+Activity+Up-Regulates+Multiple+MAP+Kinase+Pathways+and+Potentiates+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B-Induced+Differentiation+of+Human+Leukemia+HL60+Cells%2C"'>Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;-Induced Differentiation of Human Leukemia HL60 Cells,</a>" Experimental Cell Research, (2000) 258:425-437.</td></tr><tr><td class="patent-data-table-td ">82</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Wientroub, S. et al. "<a href='http://scholar.google.com/scholar?q="The+Dichotomy+in+the+Effects+of+1%2C25+Dihydroxy+Vitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Band+24%2C+25+Dihydroxy+Vitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3Bon+Bone+Gamma-Carboxyglutamic+Acid-Containing+Protein+in+Serum+and+Bone+in+Vitamin+D-Deficient+Rats%2C"'>The Dichotomy in the Effects of 1,25 Dihydroxy Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;and 24, 25 Dihydroxy Vitamin D&lt;SUB&gt;3 &lt;/SUB&gt;on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in Vitamin D-Deficient Rats,</a>" Calcif, Tissue Int., (1987) 40:166-172.</td></tr><tr><td class="patent-data-table-td ">83</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Windaus, A. et al., "<a href='http://scholar.google.com/scholar?q="Uber+das+Krystallisierte+Vitamin+D%26lt%3BSUB%26gt%3B4%26lt%3B%2FSUB%26gt%3B%2C"'>Uber das Krystallisierte Vitamin D&lt;SUB&gt;4&lt;/SUB&gt;,</a>" Z. Physiol. Chem., (1937) 247:185-188.</td></tr><tr><td class="patent-data-table-td ">84</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yu, W. et al., "<a href='http://scholar.google.com/scholar?q="Enhancement+of+1%2C25-+Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3%26lt%3B%2FSUB%26gt%3B-+Mediated+Antitumor+Activity+with+Dexamethasone%2C"'>Enhancement of 1,25- Dihydroxyvitamin D&lt;SUB&gt;3&lt;/SUB&gt;- Mediated Antitumor Activity with Dexamethasone,</a>" J. National Cancer Inst., (Jan. 1998) 90:2:134-141.</td></tr><tr><td class="patent-data-table-td ">85</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zerwekh et al., "<a href='http://scholar.google.com/scholar?q="Short-Term+1%2C25-Dihydroxyvitamin+D%26lt%3BSUB%26gt%3B3+%26lt%3B%2FSUB%26gt%3BAdministration+Raises+Serum+Osteocalcin+in+Patients+with+Postmenopausal+Osteoporosis%2C"'>Short-Term 1,25-Dihydroxyvitamin D&lt;SUB&gt;3 &lt;/SUB&gt;Administration Raises Serum Osteocalcin in Patients with Postmenopausal Osteoporosis,</a>" J. Clin. Endocrinol. Metabol, (1985) 60:615-617.</td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8466197">US8466197</a></td><td class="patent-data-table-td patent-date-value">Sep 16, 2011</td><td class="patent-data-table-td patent-date-value">Jun 18, 2013</td><td class="patent-data-table-td ">Genmedica Therapeutics Sl</td><td class="patent-data-table-td ">Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8513278">US8513278</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 2012</td><td class="patent-data-table-td patent-date-value">Aug 20, 2013</td><td class="patent-data-table-td ">Academic Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Parenteral dextrose formulation of clopidogrel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8563574">US8563574</a></td><td class="patent-data-table-td patent-date-value">Dec 7, 2010</td><td class="patent-data-table-td patent-date-value">Oct 22, 2013</td><td class="patent-data-table-td ">Academic Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Parenteral formulation of clopidogrel</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8709310">US8709310</a></td><td class="patent-data-table-td patent-date-value">Jan 4, 2012</td><td class="patent-data-table-td patent-date-value">Apr 29, 2014</td><td class="patent-data-table-td ">Hospira, Inc.</td><td class="patent-data-table-td ">Spray drying vancomycin</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20110281810">US20110281810</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Apr 13, 2011</td><td class="patent-data-table-td patent-date-value">Nov 17, 2011</td><td class="patent-data-table-td ">Cognis Ip Management Gmbh</td><td class="patent-data-table-td ">Composition</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S168000">514/168</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S167000">514/167</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0009000000">A61K9/00</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047260000">A61K47/26</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0047100000">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031592000">A61K31/592</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031590000">A61K31/59</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A01N0045000000">A01N45/00</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K9/0019">A61K9/0019</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/26">A61K47/26</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K47/10">A61K47/10</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=Mqx4BAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/592">A61K31/592</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K9/00M5</span>, <span class="nested-value">A61K47/26</span>, <span class="nested-value">A61K31/592</span>, <span class="nested-value">A61K47/10</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">May 14, 2014</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 28, 2012</td><td class="patent-data-table-td ">FPB1</td><td class="patent-data-table-td ">Expired due to reexamination which canceled all claims</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 14, 2010</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 29, 2009</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20091013</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 27, 2009</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BONE CARE INTERNATIONAL, LLC, WISCONSIN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CHANGE IN ENTITY TYPE;ASSIGNOR:BONE CARE INTERNATIONAL, INC.;REEL/FRAME:023148/0728</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20050701</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">GENZYME CORPORATION, MASSACHUSETTS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BONE CARE INTERNATIONAL, LLC;REEL/FRAME:023148/0654</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20090804</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 18, 2002</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">BONE CARE INTERNATIONAL, INC., WISCONSIN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MAZESS, RICHARD B.;DRISCOLL, JEFFREY W.;GOLDENSOPH, CREIGHTON REED;AND OTHERS;REEL/FRAME:013602/0172;SIGNING DATES FROM 20021106 TO 20021108</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2RLYKPKynaPBPxRN8zp6SYLtiC_A\u0026id=Mqx4BAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U2iYGYz8lPOYzkfGtk9WHElqBSHeQ\u0026id=Mqx4BAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U08ehckPNYN8WWTZNC9pJ_ERz5zjQ","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Improved_water_solubility_drug_delivery.pdf?id=Mqx4BAABERAJ\u0026output=pdf\u0026sig=ACfU3U1Lmkgof-YUfM5adg7gv6fDQ-mqgg"},"sample_url":"http://www.google.com/patents/reader?id=Mqx4BAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>